Vancouver, BC – TheNewswire - June 4, 2026 – Global Stocks News - Sponsored content disseminated on behalf of Cambria Gold Mines. On June 1, 2026, Cambria Gold Mines (TSXV: CAMB; OTCID: AOTVF) announced that it has begun rebuilding a 23-kilometer access road that will enable efficient transport of mineralized material from the Red Mountain project to Cambria’s 2,500-tonne-per-day mill at the Premier Mine.
The Premier Gold Project has paved road access, a 2,500 per day mill, grid-connected hydroelectric power, and proximity to a deep-water port. Multiple deposits include Premier, Silver Coin, Big Missouri, Dilworth, and Martha Ellen.
Red Mountain is a high-grade underground gold deposit, located approximately 15 kilometres northeast of Stewart, BC, within Nisga’a Nation Treaty Lands, in BC’s Golden Triangle.
Cambria Gold Mines began trading on February 13, 2026. Four months is a short timeline to complete the permitting and engineering work required to green-light construction of an access road that traverses indigenous territory.
Premier and Red Mountain are both located on Nisga'a Nation Treaty Lands. Rob McLeod, President and CEO of Cambria, has a multi-generational connection with the Nisga’a. In the late 1940s, Rob’s father, Ian McLeod, helped run election campaigns for the late Dr. Frank Calder, the first Indigenous person to serve public elected office for any provincial legislature in Canada.
“I have a long-standing personal and business relationship with Eva Clayton - President of the Nisga’a,” McLeod told Guy Bennett, the CEO of Global Stocks News (GSN), “The Nisga’a are supportive of our goal to turn both the Premier and Red Mountain assets into producing mines. There is a level of trust between us that helps expedite permitting and decision-making.”
Click Image To View Full Size
Phase 1 will focus on rebuilding a 13 km long road bed [purple section above]. It was built in 1910 as a wagon trail to access placer gold mines along Bitter Creek. Later, it was extended to the base of Red Mountain at Bromley Humps by Lac Minerals in 1994.
The road will start from the paved Highway 37A just North of Stewart. It is anticipated that mineralized material will be transported for processing at Cambria’s 2,500 tonne per day mill at the Premier Mine, for a total trucking distance of approximately 50 kilometers.
Cambria’s Red Mountain Gold Deposit hosts Measured and Indicated Resources of 3.19M tonnes averaging 7.63 g/t Au and 21.02 g/t Ag, for 783,000 ounces Au and 2,156,000 ounces Ag. The Deposit hosts additional Inferred Resources of 405,000 tonnes at 5.32 g/t Au and 7.33 g/t Ag for 69,000 ounces Au and 96,000 ounces Ag.
The deposit needs minimal infill drilling, with 544,000 ounces Au in the Measured Category at an average grade of 8.81 g/t Au. [1] The deposit has over 2,000 meters of production-size underground workings and is a wide and tabular deposit, suitable for bulk underground mining methods such as longhole stoping.
For construction of the initial road sections, work will be performed by contractor West Point Rail and Timber Co. Engineering includes work by Fortec Consulting and Onsite Engineering, with environmental monitoring by Nisga’a Growth Corp.
Cambria’s Director of Construction, Nick Stoneberger, will oversee the work. Additional contractors and consultants will be added as the road advances.
“Red Mountain is a high-grade advanced-stage project that can fuel high-margin operations,” McLeod told GSN. “Because it has a wide ore body, we believe it can produce the tonnes required to meet the capacity of the 2,500 tonne per day mill at Premier. We anticipate blending high-grade Red Mountain mineralization (75%) with bulk tonnage mineralization from Premier (25%).
To achieve this goal, we need an efficient, cost-effective transportation corridor from Red Mountain to the Premier mill. That is why we are prioritising the construction of this access road.”
Click Image To View Full Size
“Road building involves extensive environmental work,” continued McLeod, “which we are executing in partnership with the Nisga’a Nation.
The access road runs beside Bitter Creek. It’s fed by glaciers, which bring fine-grained material called rock flour. As a fish habitat, it’s poor. There's no salmon, but you do get a few Dolly Varden trout.
On average, every fifty years, there’s a severe weather event that could cause sections of the access road to wash into the creek, negatively impacting the trout. For this reason, the Department of Fisheries & Oceans requires us to do a ‘fish offset’ – enhancing salmon habitat elsewhere. Working with the Nisga’a, we selected areas up in the Bear River Valley, where I used to fish as a kid.
In the late fall, when the salmon come up the rivers to spawn, they get slaughtered by eagles because there are no trees to provide cover. We are going to realign some creeks, put in stumps, old dead trees, archways, and narrow the channels so the vegetation can grow thicker. This will make it harder for the eagles to hunt the spawning salmon.”
Click Image To View Full Size
Above: Red Mountain Access Trail
“We also have a goat management plan that would restrict hunting,” McLeod told GSN. “When the wild goats are getting ready to have their babies, you don’t want to disturb them. The goats go high up into the alpine areas, where there is no chance we would stumble on them, but we limit the use of helicopters above 500 feet of elevation during the goat birthing season.”
There’s also an indigenous man who operates a trap line in the vicinity of the access road. He's an old family friend. We’ve consulted him, made sure that our mining activities do not threaten his livelihood.”
“In the Golden Triangle, eagles, goats and trap-lines have environmental, cultural and economic importance,” added McLeod, “These are things the Nisga’a know a lot about. Having them as partners is helping us to improve and expedite our development and exploration programs.”
The original Cambria Gold press release is available here.
1. For additional information on the Red Mountain resource numbers, refer to the NI 43-101 Technical Report “Premier & Red Mountain Gold Project Feasibility Study” with a report date of May 22, 2020. The Red Mountain resource was authored by Gilles Arseneau, P.Geo., a Qualified Person as defined by NI 43-101.
Disclaimer: Cambria Gold Mines paid Global Stocks News (GSN) $1,750 for the research, writing and dissemination of this content.
Full Disclaimer: GSN researches and fact-checks diligently, but we cannot ensure our publications are free from error. Investing in publicly traded stocks is speculative and carries a high degree of risk. GSN publications may contain forward-looking statements such as “project,” “anticipate,” “expect,” which are based on reasonable expectations, but these statements are imperfect predictors of future events. When compensation has been paid to GSN, the amount and nature of the compensation will be disclosed clearly.
Premier African Minerals Ltd (AIM:PREM, OTC:PRMMF) shares surged 17% to 0.027p after the company reported a key milestone in the restart of operations at its Zulu lithium and tantalum project in Zimbabwe.
The mining group said ore from the run-of-mine stockpile is now being fed through the newly installed flotation plant, marking the latest step in efforts to bring the project back into production.
Premier said initial observations have been encouraging, with the flotation plant operating as expected following commissioning.
However, the company cautioned that it remains at an early stage in the optimisation process and it is too soon to comment on recovery rates or overall plant performance.
Managing director Graham Hill said: "Initial observations are positive and the flotation plant is operating as expected."
He added that ongoing analysis and optimisation work is continuing and further updates would be provided in due course.
The flotation circuit is a critical part of the processing plant and is intended to concentrate lithium-bearing minerals from ore mined at Zulu.
Investors welcomed the update as a sign that the long-delayed restart of the project is progressing. The company has spent recent months installing and commissioning the revised processing plant following previous operational difficulties.
Hill described the commencement of ore processing through the flotation plant as "a very positive step in the re-start of Zulu" and praised the site's operational team for completing the installation.
The company said further operational updates will follow as optimisation work progresses and performance data becomes available.
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Cambria Gold Mines Inc. (TSXV: CAMB) (OTCQX: CAMVF) ("Cambria" or the "Company") is pleased to announce the first results from the underground infill program at the Prew Zone and additional surface drilling results from the 602 Zone at the Premier Gold Project ("PGP"), located in northwestern British Columbia. Two underground and one surface drills are currently active on site. Results from a total of 15 underground drillholes and nine surface drillholes are reported herein, with results including:
19.82 g/t Au over 5.0 m (incl. 45.88g/t Au over 2.0 m) in hole P26U-0003 at Prew Zone14.96 g/t Au over 6.3 m (incl. 24.50 g/t Au over 3.0m) in hole P26U-0007 at Prew Zone11.38 g/t Au over 7.0 m (incl. 26.56 g/t Au over 2.9 m) in hole P26U-0008 at Prew Zone7.24 g/t Au over 9.0 m (incl. 12.93g/t Au over 3.0 m) in hole P26U-0016 at Prew Zone483.0 g/t Au over 1.0 m in hole P26U-0011 at Prew Zone9.82 g/t Au over 12.2 m (incl. 15.62 g/t Au over 4.0 m) in hole P26-2694 at 602 Zone"These results are demonstrating the continuity of gold grade and host structure at the Prew and 602 Zones, located down-dip from the famous Premier Gold Mine," said Robert McLeod, President and CEO of Cambria Gold Mines. "We will continue to infill the Premier deposit over the coming weeks before targeting the Big Missouri and Silver Coin Deposits located further north of the Premier mine and mill."
Drilling at the Premier-Northern Lights Deposit, ("PNL") Prew Zone in 2026 has been planned as closely-spaced delineation drillholes on average 12.5m centres from underground platforms to support development planning as the Company works toward a potential restart of operations. Cambria is of the opinion that the previous surface drilling at 25m average spacing was too wide to allow for accurate modelling of mineralized zones. This was likely a significant contributor to the difficulties encountered when the Premier Project was in operation, previously under Ascot Resources Ltd.'s prior management team.
Results from the ongoing 2026 infill program have been positive, with continuity of mineralization defined, especially within a primary quartz-breccia sulfide domain traceable in previous drilling and the underground workings (See Figure 3). High-grade gold mineralization was encountered in this domain at the "310 Face" by the last underground development round blasted in 2025, prior to the mine being placed on care and maintenance.
Mineralization at the Prew Zone consists of quartz-breccia with infilling sulfide mineralization, and in some cases includes visible gold. Close drill spacing is also proving effective in the modelling of post mineral faults which offset and affect the orientation of mineralized zones in the Prew Zone.
In addition to the underground drilling at Prew, results from an additional nine completed drillholes were received from the 602 Zone of the PNL deposit. These infill holes were drilled from surface due to limited underground access options. The 602 Zone mineralization consists of similar quartz-sulfide cemented breccias and veins to that seen at Prew and could be accessed in the future with additional underground development.
Cambria anticipates the underground drill program at Prew Zone to continue into early Q3 2026. Surface drilling is planned to transition to the Silver Coin and Big Missouri deposits in early July 2026 when summer access opens. The Company intends to complete a total of 27,000m of infill development drilling this year across the Premier Project deposits.
Figure 1: Plan map of Premier-Northern Lights (PNL) deposit showing 2026 target zones
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4267/300658_15a1fd7454a84993_001full.jpg
Figure 2: Plan map showing Prew Zone underground drill plan including assays received, drilled holes with assays pending, and ongoing drilling areas
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4267/300658_15a1fd7454a84993_002full.jpg
Figure 3: Cross section of Prew Zone infill drilling showing new reported drill results
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4267/300658_15a1fd7454a84993_003full.jpg
Figure 4: Visible gold intersection in hole P26U-0011 at 20 metres downhole depth
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4267/300658_15a1fd7454a84993_004full.jpg
Figure 5: Long Section of 602 Zone showing new and previously reported 2026 drill results (See April 21, 2026 Cambria Gold News Release for previously reported 2026 results)
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4267/300658_15a1fd7454a84993_005full.jpg
P26U-000107.77.75.286.64578215094%10.38 g/t Au over 3.5 mP26U-000206.56.57.3110.65272327174%11.16 g/t Au over 4.0 mP26U-000211198.01.973.32739132973%
P26U-0003055.019.8212.18165416743%45.88 g/t Au over 2.0 mP26U-000412.7218.45.217.54486251198%14.72 g/t Au over 2.4 mP26U-000424.4305.61.984.51597105398%
P26U-000578.51.520.0928.812507484398%
P26U-00068113.19.3317.311329498590%
P26U-000617214.03.425.2222473890%
P26U-000720.8276.314.9616.515689673796%24.5 g/t Au over 3.0 mP26U-000822297.011.3816.19215457187%26.56 g/t Au over 2.87 mP26U-001040.846.55.710.0171316104075%44.7 g/t Au over 1.0 mP26U-001120211.0483.0011724721397%
P26U-001127358.01.945.12244144097%
P26U-001137381.012.251.6104530897%
P26U-001143.55410.51.303.8188693697%
P26U-001227336.06.3714.34682353396%
P26U-00133.6128.44.678.82405247682%
P26U-00133439.55.53.5414.911133506382%
P26U-001638479.07.2413.27504335074%12.93 g/t Au over 3.0 mP26U-005328.6345.416.0513.1136370899%82.30 g/t Au over 1.0 m
602 Zone Surface Drilling
P26-26913403487.62.79143030187391%
P26-26923363382.05.86779.312736237087%
P26-26933073092.07.6516.623185643099%
P26-26933183191.038.1015.24080116099%
P26-2694307319.212.29.82239841871897%15.62 g/t Au over 4.0 mP26-2694326331.85.82.3924.932171392397%
P26-2695A3423497.32.1550.411326533883%
P26-26973173181.025.5025.4272088899%
1 - ETW = Estimated True Width. All reported intervals are down-hole lengths, with true width estimates ranging from 43-99% of the reported interval. True widths are estimated based on the angle of the drill hole with the interpreted trend of the mineralized zones.
Composite Calculations for Significant Intersections
Composites for significant intersections were calculated using a 1g/t gold (Au) cut off grade and maximum 3m internal waste. "Including" results are reported at a 10g/t Au cut off grade with maximum 3m internal waste.
Table 2: Drill Collar Locations and Hole Orientations
The Company maintains a rigorous sampling and QA/QC procedure for the 2026 drill program. Core samples are prepared at the ALS preparation lab in Terrace, BC. The samples are dried and then crushed to specifications of 70% passing 2mm. Crushed samples are riffle split to 1000g and pulverized to 85% passing 75µm.
Analytical work for all results is completed by ALS Canada Ltd. which maintains an internal quality assurance and quality control (QAQC) program and is ISO:17025 certified for the analytical methods used in this release. Pulp splits are sent directly from the Terrace preparation facility to the ALS Canada Ltd. geochemistry laboratory facility in North Vancouver for analysis. Each sample is analyzed for gold by conventional 50g fire assay with atomic absorption finish (Au-AA26) and multielement analysis by four-acid digest with an ICP finish (ME-ICP61).
Samples over 100ppm gold are re-analyzed by an overlimit 50g fire assay with a gravimetric finish (Au-GRA22). Samples over 100ppm silver are re-analyzed with an ore grade method (ME-OG62) which is a four-acid digest method followed by an ICP-AES finish (up to 1,500ppm). Samples over 1,500ppm silver trigger the overlimit silver fire assay method (Ag-GRA21) which uses a 30g aliquot and gravimetric finish. Sampling and storage activities are conducted at the Company's secure facility in Stewart, British Columbia.
The Company maintains a QAQC program that includes the submission and review of coarse blank materials to monitor contamination and certified reference materials to assess analytical accuracy. Core duplicates, crush duplicates and pulp duplicates are used to infer sampling precision and nugget effect.
Qualified Person and Technical Information:
The scientific and technical information within this news release was reviewed and approved by Blaine Smit, P.Geo. Vice President Exploration for Cambria Gold Mines Inc. Mr. Smit is a "Qualified Person" as defined under National Instrument 43-101. To verify the information related to this news release, Mr. Smit visited the 2026 drilling operations to review and discuss logging, sampling, and shipping procedures with responsible site staff, and reviewed and discussed assay and QA/QC results with responsible company personnel.
About Cambria Gold Mines
Cambria Gold Mines is a Canadian mining company headquartered in Vancouver, British Columbia, and its shares trade on the TSX-V under the ticker CAMB and on the OTCID under the ticker AOTVF. Cambria is the 100% owner of the Premier Gold mine and Red Mountain Gold Project that are located on Nisga'a Nation Treaty Lands, in the prolific Golden Triangle of northwestern British Columbia and the Mt. Margaret Copper-Gold Porphyry deposit located in Washington State. For more information about the Company, please refer to the Company's profile on SEDAR+ at www.sedarplus.ca or visit the Company's web site at www.cambriagold.com.
On behalf of the Board of Directors of Cambria Gold Mines Inc.
Robert McLeod
CEO and Director
Cautionary Statements:
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary Statement Regarding Forward-Looking Information
All statements and other information contained in this press release about anticipated future events may constitute forward-looking information under Canadian securities laws ("forward-looking statements"). Forward- looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "targeted", "outlook", "on track" and "intend" and statements that an event or result "may", "will", "should", "could", "would" or "might" occur or be achieved and other similar expressions. All statements, other than statements of historical fact, included herein are forward-looking statements, including statements in respect of: the ability of the Company to accomplish its business objectives and the intentions described herein; the potential resource growth and subsequent operational ability of the PNL Prew and 602 Zones; future production at the Premier Gold Mine; the potential economics of the Premier Project; anticipated drilling to occur for the remainder of 2026; any untapped growth potential at the Prew Zone; and the Company's future objectives and plans. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements, risks relating to negative operating cash flows of the Company; business and economic conditions in the mining industry generally; fluctuations in commodity prices and currency exchange rates; environmental compliance; risks related to outstanding debt; uncertainty of estimates and projections relating to development, production, costs and expenses, and health, safety and environmental risks; uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; the need to obtain additional financing to finance operations and uncertainty as to the availability and terms of future financing; social media and reputation; negative publicity; human rights; business objectives; shortage of personnel; health and safety; the possibility of delay in future plans and uncertainty of meeting anticipated program milestones; claims and legal proceedings; information systems and cyber security; internal controls; violation of anti-bribery or corruption laws; competition; tax considerations; compliance with listing standards; enforcement of civil liabilities; financing requirement risks; market price volatility of the common shares; uncertainty as to timely availability of permits and other governmental approvals; the need for exchange approval, and other regulatory approvals and other risk factors as detailed from time to time in Cambria's filings with Canadian securities regulators, available on Cambria's profile on SEDAR+ at www.sedarplus.ca including the Annual Management Discussion and Analysis for the year ended December 31, 2025 in the section entitled "Risk Factors". Forward-looking statements are based on assumptions made with regard to: the estimated costs associated with the care and maintenance plans; the tax rate applicable to the Company; future commodity prices; the grade of mineral resources and mineral reserves; labor and materials costs increasing on a basis consistent with the Company's current expectations, the ability of the Company to convert inferred mineral resources to other categories; the ability of the Company to reduce mining dilution; the ability to reduce capital costs; the ability of the Company to raise additional financing; currency exchange rates being approximately consistent with current levels, compliance with the covenants in Cambria's credit agreements; exploration plans; and general marketing, political, business and economic conditions. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Although Cambria believes that the expectations reflected in such forward-looking statements and/or information are reasonable, undue reliance should not be placed on forward-looking statements since Cambria can give no assurance that such expectations will prove to be correct. Cambria does not undertake any obligation to update forward-looking statements, other than as required by applicable laws. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300658
Source: Cambria Gold Mines Inc.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- RideNow Group, Inc. (NASDAQ: RDNW) ("we", "our", the "Company", or "RideNow"), a leading U.S. powersports vehicle retailer, today announced the opening of a new flagship facility for RideNow Tallahassee. In its move to 3213 Apalachee Pkwy, the dealership has tripled its footprint to 27,000 square feet, creating a comprehensive destination designed to better support the needs of the Florida Panhandle riding community.
Rendering of the new RideNow Powersports dealership in Tallahassee, Florida. The new facility represents a total reimagining of the customer experience. By increasing staffing levels by 25% and creating a site with easier entrance and exit for customer parking, RideNow Tallahassee is prioritizing the convenience and service standards that riders demand. The expansion also features a state-of-the-art service department and a massive new accessory and clothing section, boasting a large selection of riding gear.
"Moving into our new powersports facility is a huge milestone for our team and customers," said Jon Buck, General Manager of RideNow Tallahassee. "With nearly three times the space, we can bring in more inventory than ever before — giving our customers the largest selection in the Florida Panhandle for on-road motorcycles, off-road machines, personal watercraft, Polaris Slingshots, and Yamaha boats, along with a massive lineup of riding gear and accessories. We're beyond excited to welcome everyone into our new showroom and deliver an even better buying and riding experience."
The dealership now offers an extensive roster of the top powersports brands, including Honda, Yamaha, Suzuki, Kawasaki, CFMOTO, Royal Enfield, and Club Car. A major highlight of the move is the addition of Polaris Off-Road vehicles to the Tallahassee market. With a vast selection of both new and used ATVs, UTVs, personal watercraft, and motorcycles, riders of all levels will find a machine suited for any adventure.
"This expansion marks another exciting chapter in our long-standing partnership with Polaris Industries," said Cam Tkach, Chief Operating Officer of RideNow Group, Inc. "RideNow Tallahassee is now our 30th Polaris store, reinforcing our commitment to delivering the full lineup of Polaris off-road vehicles to riders across the country. Together with Polaris, we're proud to bring world-class powersports experiences to the Florida Panhandle."
Looking ahead, RideNow Tallahassee plans to expand its service to seven days a week and will serve as a community cornerstone by hosting monthly Bike Nights and other onsite events.
About RideNow Group, Inc.
RideNow Group, Inc. is a premier powersports dealership group and is believed to be the largest powersports retail group in the United States. The Company offers an extensive selection of new and pre-owned motorcycles, all-terrain vehicles, utility terrain or side-by-side vehicles, personal watercraft, snowmobiles, and other powersports vehicles. RideNow also offers parts, apparel, accessories, and finance and insurance services, including aftermarket products from a wide range of manufacturers. As a leading purchaser of pre-owned inventory, the Company leverages its proprietary RideNow Cash Offer tool to acquire vehicles directly from consumers. Learn more about RideNow at https://www.ridenow.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which may be identified by words such as "expects," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including, but not limited to, the risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
MEXICO CITY, June 10, 2026 (GLOBE NEWSWIRE) -- Premier Graphene Inc. (OTC: BIEI) (“Premier” or the “Company”) today announced that its Mexican affiliate, HGI Industrial Technologies S.A.P.I. (“HGI”), has been awarded two new contracts to supply the Mexican military. The contracts cover (1) Military Tactical Belts and (2) Nylon-Cotton Ripstop Fabric — both mission-critical materials within active defense supply programs. HGI and Premier have already commenced coordination with suppliers, manufacturers, and logistics partners to ensure timely and efficient fulfillment.
These awards represent more than individual contract wins. They reflect a pattern of repeat business and growing institutional confidence in HGI’s ability to source, coordinate, and deliver across multiple supply categories. For investors, the contract awards offer several important signals:
Recurring defense revenue: The awards follow prior military supply work, indicating an established customer relationship and a repeatable, revenue-generating business model within the Mexican defense sector.Immediate execution underway: Coordination with suppliers and logistics partners has already begun, positioning the companies for on-time delivery and efficient contract performance.Scalable supply chain infrastructure: The ability to fulfill contracts spanning tactical equipment and technical fabrics demonstrates operational breadth and a platform capable of supporting additional contract categories.Diversified revenue alongside a technology pipeline: While HGI with help from Premier advances its proprietary graphene and advanced materials initiatives, the defense contracting business provides near-term, tangible revenue that complements the Company’s longer-term technology development strategy.Strategic regional positioning: With established operations and relationships in Mexico and broader Latin America, Premier and HGI are well-placed to pursue additional defense and government supply opportunities across the region.
Pedro Mendez, President of both Premier Graphene Inc. and HGI Industrial Technologies, commented:
“We are honored by the confidence placed in our team through these contract awards. These opportunities further strengthen our position within the defense supply chain and demonstrate our ability to deliver quality products, reliable logistics, and effective execution. We look forward to expanding our presence in the defense sector while continuing to pursue opportunities in advanced materials, graphene technologies, aerospace applications, rare earth materials and other strategic industries.”
The defense supply contracts sit within a broader strategic growth plan that Premier and HGI are executing across several high-value verticals. The companies are actively pursuing the following initiatives in parallel with their defense supply activities:
Proprietary graphene production: Premier and HGI are developing graphene production technologies within Mexico and the U.S derived from biomass feedstocks — a potentially lower-cost, more sustainable pathway to commercial-scale graphene supply, with applications spanning defense, aerospace, electronics, and energy.Defense and aerospace applications: The companies are identifying opportunities to apply advanced materials, including graphene-enhanced composites and coatings, within defense and aerospace programs across North America and Latin America.Quantum-related materials research: Premier and HGI are pursuing early-stage opportunities in quantum-related materials, related to industrial hemp graphene a field attracting growing government and commercial investment.Critical minerals and rare earth resources: The Companies are exploring graphene-bearing and rare earth mineral resources in Brazil and Mexico, aligned with global demand for domestically sourced critical materials and North American supply chain resilience. Together, these efforts position Premier's affiliate HGI as a multi-vertical company with near-term defense revenue, a developing advanced materials technology platform, and exposure to high-growth sectors including aerospace, quantum materials, and critical minerals. Management expects to provide additional detail on contract quantities, delivery timelines, and financial impact as information becomes available, and will continue to disclose material developments as they occur.
About HGI Industrial Technologies S.A.P.I.
HGI Industrial Technologies S.A.P.I. is a Mexican technology and industrial solutions company focused on advanced materials, proprietary graphene development, rare earth mineral mining , defense-sector opportunities, aerospace technologies, manufacturing partnerships, and strategic resource development initiatives. The Companies are actively exploring multiple commercial and government applications for graphene and other advanced materials.
About Premier Graphene Inc.
Premier Graphene Inc. is focused on the commercialization and development of graphene technologies, advanced materials, aerospace and defense applications, critical mineral opportunities, and strategic investments designed to create long-term shareholder value. Premier Graphene is working to be a supplier of pristine graphene for the U S. Govt as well as the U.S. military industrial complex as soon as ITAR certification is approved.
Forward-Looking Statements
This press release contains forward-looking statements regarding future business opportunities, graphene technology development, aerospace initiatives, critical mineral projects, and expected operational activities. Actual results may differ materially due to customer requirements, procurement processes, regulatory approvals, market conditions, and other factors beyond the Company's control. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release.
Media Contact:
President of HGI Industrial Technologies SAPI / Premier Graphene Inc.
Pedro Alberto Méndez [email protected]
www.premiergrapheneinc.com
www.hgiindustrialtechnologies.com
To get the latest news on the exciting developments from Premier Biomedical Inc. (OTC: BIEI), now known as Premier Graphene, Inc., subscribe by submitting to:
https://premiergrapheneinc.com/contact/
https://www.linkedin.com/in/pedro-mendez-a504741ba
For more information, please contact us at: [email protected]
Website (upgrading in process): https://premiergrapheneinc.com/
X: @PREMIERGRAPHENE
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Words such as “anticipate,” “expect,” “believe,” “intend,” and similar expressions are intended to identify such forward-looking statements. Premier Graphene Inc. undertakes no obligation to update or revise these statements except as required by law.
Contact:
Premier Graphene Inc.
Investor Relations
El Centro, California [email protected]
www.premiergrapheneinc.com
, /PRNewswire/ -- Federated Hermes Premier Municipal Income Fund (NYSE: FMN) has declared a dividend. The fund seeks to provide investors with current dividend income that is exempt from regular federal income tax. In addition, this fund features income exempt from the federal alternative minimum tax (AMT).
Tax-Free Dividend Per Share
Record Date:
June 23, 2026
Ex-Dividend Date:
June 23, 2026
Payable Date:
July 1, 2026
Amount
Change From Previous Month
$0.0450
$0.0000
Investors can view additional portfolio information in the Products section of FederatedHermes.com/us.
Federated Hermes, Inc. (NYSE: FHI) is a global leader in active, responsible investment management, with $907.1 billion in assets under management, as of March 31, 2026. We deliver investment solutions that help investors target a broad range of outcomes and provide equity, fixed-income, alternative/private markets, multi-asset and liquidity management strategies to more than 11,000 institutions and intermediaries worldwide. Our clients include corporations, government entities, insurance companies, foundations and endowments, banks and broker/dealers. Headquartered in Pittsburgh, Federated Hermes has more than 2,000 employees in London, New York, Boston and offices worldwide. For more information, visit FederatedHermes.com/us.
Alexandria, VA, USA, June 10, 2026 (GLOBE NEWSWIRE) -- Bluesight, the leader in hospital intelligence solutions, has been awarded a national group purchasing agreement for Pharmacy Technology Solutions with Premier, Inc. Effective May 1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Bluesight’s full suite of solutions, including those in key categories: drug diversion surveillance, purchasing optimization, 340B compliance, shortage management, RFID inventory management, and patient privacy monitoring.
This partnership simplifies and accelerates the procurement process, enabling healthcare providers to quickly acquire, implement, and derive value from new technologies.
Building on a foundation of trust that spans more than a decade, this new agreement marks a significant evolution in the long-standing relationship between Bluesight and Premier. What began as a focused collaboration on inventory management and diversion monitoring has now matured into a comprehensive strategic partnership, granting members seamless access to Bluesight’s entire suite of solutions under a single, unified framework.
"Our mission has always been to provide hospitals with the visibility they need to improve patient safety and operational efficiency," said Kevin MacDonald, CEO and Co-Founder of Bluesight. "By formalizing and expanding our work with Premier, we are making it easier than ever for their extensive network of member organizations to access our entire portfolio of solutions at a significant value.” MacDonald continued, “We are excited to showcase our full suite of solutions to Premier members at Premier’s Breakthroughs Conference this October in National Harbor, MD."
About Bluesight’s Solutions
Bluesight’s comprehensive ecosystem is designed to eliminate manual workflows and mitigate risk across the pharmacy supply chain. It includes:
Drug Diversion Surveillance: Confirm and prevent drug diversion across nursing, OR, inpatient pharmacy, and retail pharmacy locations.Purchasing Optimization: Unite industry-wide pricing data with your contracts to streamline procurement decisions and reduce medication spend.340B Compliance: Maintain 100% compliance oversight and audit readiness for your 340B program.Shortage Management: Combine predictive analytics, inventory data, and collaborative planning tools to manage predicted shortages proactively.RFID Inventory Management: Leverage RFID to eliminate expirations, prevent stockouts, and maintain accuracy across inventory in kits, trays, fridges, and shelves.Patient Privacy Monitoring: Monitor up to 100% of system accesses to uncover hidden privacy violations before they escalate. Premier is a leading technology-driven healthcare improvement company. Playing a critical role in the rapidly evolving healthcare industry, Premier unites providers, suppliers and payers to make healthcare better with national scale, smarter with actionable intelligence and faster with novel technologies. Headquartered in Charlotte, N.C., Premier offers integrated data and analytics, collaboratives, supply chain solutions, advisory services, and other solutions in service of their mission to improve the health of communities.
About Bluesight
Bluesight enables hospital operations with intelligence that simplifies inventory management, procurement, and compliance. Through its suite of industry-leading, AI-powered solutions, Bluesight ensures that health systems protect every patient and optimize every dollar. Over 3,000 United States and Canadian hospitals rely on Bluesight every day. For more information, please visit bluesight.com.
Bluesight Awarded Pharmacy Technology Solutions Agreement with Premier, Inc.
Bluesight Awarded Pharmacy Technology Solutions Agreement with Premier, Inc. Bluesight Awarded Pharmacy Technology Solutions Agreement with Premier, Inc.
Contact Data Account Executive Amanda Montini Brodeur Partners for Bluesight [email protected]
[url="]PGIM[/url], the $1.4 trillion global asset management business of Prudential Financial, Inc.1 ([url="]NYSE: PRU[/url]), has launched a market- different
In a February 17, 2026, filing, Inherent Management Corp. disclosed buying 200,050 Sotera Health Company (SHC 0.55%) shares, an estimated $3.31 million trade based on quarterly average pricing.
What happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Inherent Management Corp. increased its position in Sotera Health Company (SHC 0.55%) by 200,050 shares during the fourth quarter. The estimated value of shares acquired is approximately $3.31 million, based on the average closing price for the period. At quarter-end, the position’s reported value rose by $5.39 million, a figure that incorporates both the additional shares and changes in Sotera Health's share price.
What else to knowInherent Management Corp. executed a buy; Sotera Health now accounts for 10.6% of the fund's 13F assets under management.Top holdings after the filing:NYSEMKT:VEA: $73.18 million (37.6% of AUM)NYSEMKT:IEMG: $27.94 million (14.3% of AUM)NASDAQ:PAX: $23.58 million (12.1% of AUM)NYSE:NEE: $20.87 million (10.7% of AUM)NASDAQ:SHC: $20.69 million (10.6% of AUM)As of Friday, Sotera Health shares were priced at $13.50, up 13% over the past year and underperforming the S&P 500’s roughly 16% gain in the same period.Company overviewMetricValueRevenue (TTM)$1.16 billionNet Income (TTM)$77.9 millionPrice (as of Friday)$13.50Company snapshotSotera Health provides sterilization services (gamma, electron beam, EO processing), lab testing, and advisory solutions for medical device, pharmaceutical, food, and specialty industries.The firm generates revenue from sterilization, laboratory testing, and advisory services.It serves medical device manufacturers, pharmaceutical companies, and clients in food, agriculture, and specialty commercial sectors globally.Sotera Health Company is a leading provider of sterilization and lab testing services, supporting critical supply chains in healthcare and related industries. The company operates at scale, with a diversified customer base and an emphasis on regulatory compliance and quality assurance. Its integrated service offerings and global reach position it as a key partner for organizations requiring stringent safety and testing standards.
What this transaction means for investorsSotera is still executing. The business just posted its 20th consecutive year of revenue growth, with sales rising about 6% to $1.16 billion and adjusted EBITDA climbing to nearly $600 million. So the problem seems like perception. Shares are down roughly 23% since the end of last quarter, and concerns around litigation exposure, leverage, and regulatory scrutiny have overshadowed otherwise stable fundamentals. Even with improving net income and a stronger balance sheet, investors have been quick to de-risk. And that’s manifested itself, in part, through sentiment over a substantial secondary shares, during which existing investors offloaded 25 million shares this month. Those existing investors were affiliated with private equity firms Warburg Pincus and GTCR, the types of investors that tend to exit positions after a few years anyway.
Within a portfolio dominated by broad ETFs and defensive exposures like NextEra Energy, this position stands out as a more concentrated, idiosyncratic bet. At over 10% of assets, it signals conviction in the firm’s fundamentals, perhaps even regardless of recent price movement.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends NextEra Energy and Vanguard FTSE Developed Markets ETF. The Motley Fool has a disclosure policy.
On February 17, 2026, Sessa Capital disclosed a major buy of Sotera Health (SHC 0.55%), adding 10,630,381 shares in an estimated $175.80 million trade based on quarterly average pricing.
What happenedAccording to a filing with the Securities and Exchange Commission dated February 17, 2026, Sessa Capital purchased 10,630,381 additional shares of Sotera Health in the fourth quarter. The estimated transaction value is $175.80 million, calculated using the average closing price for the quarter. The fund’s quarter-end position value in Sotera Health rose by $206.47 million, a figure reflecting both trading activity and stock price movement.
What else to knowThe post-trade stake represents close to 7% of Sessa Capital’s 13F reportable assets under management.Top holdings after the filing:NASDAQ: WBD: $1.31 billion (26.1% of AUM)NYSE: HUM: $593.94 million (11.8% of AUM)NASDAQ: ILMN: $446.48 million (8.9% of AUM)NYSE:PCG: $394.97 million (7.9% of AUM)NYSE:COF: $377.65 millino (7.5% of AUM)As of Monday, SHC shares were priced at $13.99, up 18% over the past year and slightly outperforming the S&P 500’s roughly 15% gain in the same period as a result.Company overviewMetricValuePrice (as of Monday)$13.99Market capitalization$4.0 billionRevenue (TTM)$1.2 billionNet income (TTM)$77.9 millionCompany snapshotSotera Health offers sterilization services (gamma, electron beam, and EO processing), laboratory testing, and advisory solutions for medical device, pharmaceutical, and related industries.The firm serves medical device manufacturers, pharmaceutical companies, and food/agricultural product providers globally.It maintains a global footprint with a diversified revenue base and high customer retention.Sotera Health is a leading provider of sterilization and lab testing services, supporting critical supply chains in healthcare and life sciences. With specialized technology and regulatory expertise, it maintains recurring revenue streams and serves as a key partner to medical and pharmaceutical manufacturers worldwide.
What this transaction means for investorsSotera has built a strong track record in healthcare services, with revenue reaching about $1.16 billion and adjusted EBITDA close to $600 million last year, marking 20 years of steady growth. Typically, this kind of consistent performance commands a premium. However, the stock has dipped since the last quarter as investors focus on risks from litigation, high leverage, and regulatory concerns.
Additionally, the market has been flooded with supply. A recent secondary offering saw private equity backers dump 25 million shares, creating a technical overhang that doesn't reflect Sotera's underlying fundamentals.
In the broader portfolio, this mirrors a trend. Substantial positions in companies like Warner Bros. Discovery and Illumina indicate a willingness to embrace controversy while fundamentals remain strong, and Sotera is just outside the firm’s top five holdings by value.
For long-term investors, the crucial question is about durability. If Sotera can maintain mid-single-digit growth and effectively handle litigation risks, this recent gap between its actual performance and investor perception won't last forever.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Warner Bros. Discovery. The Motley Fool recommends Capital One Financial and Illumina. The Motley Fool has a disclosure policy.
Sotera Health (SHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sotera Health Company (NASDAQ:SHC – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven brokerages that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $20.4286.
Several research analysts have weighed in on the company. Zacks Research lowered Sotera Health from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Piper Sandler raised Sotera Health from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $17.00 to $24.00 in a research report on Friday, January 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Sotera Health in a report on Monday, December 29th. William Blair initiated coverage on Sotera Health in a research report on Thursday, December 18th. They issued an “outperform” rating for the company. Finally, Wells Fargo & Company downgraded shares of Sotera Health to an “overweight” rating in a report on Thursday, January 8th.
Get Our Latest Stock Report on Sotera Health
Insider Buying and Selling at Sotera Health In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $15.27, for a total transaction of $152,700,000.00. Following the completion of the sale, the director owned 12,735,301 shares of the company’s stock, valued at $194,468,046.27. This represents a 43.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 47.55% of the stock is owned by company insiders.
Hedge Funds Weigh In On Sotera Health Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System lifted its holdings in shares of Sotera Health by 1.4% in the third quarter. Arizona State Retirement System now owns 46,183 shares of the company’s stock valued at $726,000 after purchasing an additional 621 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Sotera Health by 10.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,204 shares of the company’s stock worth $127,000 after buying an additional 705 shares in the last quarter. Strs Ohio raised its position in Sotera Health by 17.4% in the 4th quarter. Strs Ohio now owns 4,895 shares of the company’s stock valued at $86,000 after buying an additional 727 shares during the last quarter. Federated Hermes Inc. lifted its stake in Sotera Health by 6.0% in the 4th quarter. Federated Hermes Inc. now owns 16,676 shares of the company’s stock valued at $294,000 after acquiring an additional 944 shares in the last quarter. Finally, First Citizens Bank & Trust Co. lifted its stake in Sotera Health by 1.5% in the 4th quarter. First Citizens Bank & Trust Co. now owns 66,266 shares of the company’s stock valued at $1,169,000 after acquiring an additional 970 shares in the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.
Sotera Health Stock Up 0.6% Shares of NASDAQ SHC opened at $14.96 on Friday. Sotera Health has a 52-week low of $9.53 and a 52-week high of $19.85. The company has a debt-to-equity ratio of 3.66, a quick ratio of 2.24 and a current ratio of 2.46. The stock has a market cap of $4.25 billion, a P/E ratio of 55.41 and a beta of 1.88. The firm has a 50 day moving average price of $15.92 and a 200 day moving average price of $16.53.
Sotera Health (NASDAQ:SHC – Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.02. Sotera Health had a net margin of 6.70% and a return on equity of 42.38%. The company had revenue of $303.44 million for the quarter, compared to analyst estimates of $300.68 million. During the same period last year, the business posted $0.21 earnings per share. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. Sotera Health has set its FY 2026 guidance at 0.930-1.01 EPS. Analysts expect that Sotera Health will post 0.61 EPS for the current year.
About Sotera Health (Get Free Report)
Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.
Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.
Recommended Stories Five stocks we like better than Sotera Health
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEWatsco, Inc. (NYSE:WSO) Receives Consensus Rating of “Hold” from Analysts
NEXT HEADLINE »Archer Aviation Inc. (NYSE:ACHR) Given Consensus Recommendation of “Moderate Buy” by Analysts
Capricorn Fund Managers Ltd purchased a new position in Sotera Health Company (NASDAQ:SHC – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 449,900 shares of the company’s stock, valued at approximately $7,936,000. Sotera Health makes up 1.9% of Capricorn Fund Managers Ltd’s investment portfolio, making the stock its 15th biggest position. Capricorn Fund Managers Ltd owned approximately 0.16% of Sotera Health as of its most recent filing with the SEC.
Other hedge funds also recently bought and sold shares of the company. Nordea Investment Management AB acquired a new position in Sotera Health in the 4th quarter worth approximately $1,908,000. Exchange Traded Concepts LLC acquired a new stake in Sotera Health during the 4th quarter valued at $7,739,000. Hudson Bay Capital Management LP purchased a new stake in shares of Sotera Health in the third quarter valued at $3,932,000. Voss Capital LP lifted its holdings in shares of Sotera Health by 50.0% in the second quarter. Voss Capital LP now owns 750,000 shares of the company’s stock valued at $8,340,000 after purchasing an additional 250,000 shares in the last quarter. Finally, CenterBook Partners LP acquired a new stake in shares of Sotera Health in the third quarter worth $1,228,000. 91.03% of the stock is owned by hedge funds and other institutional investors.
Sotera Health Price Performance SHC stock opened at $14.96 on Monday. The firm has a market cap of $4.25 billion, a PE ratio of 55.41 and a beta of 1.88. Sotera Health Company has a 1 year low of $9.53 and a 1 year high of $19.85. The company has a fifty day simple moving average of $15.85 and a 200 day simple moving average of $16.53. The company has a current ratio of 2.46, a quick ratio of 2.24 and a debt-to-equity ratio of 3.66.
Sotera Health (NASDAQ:SHC – Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.24 by $0.02. Sotera Health had a net margin of 6.70% and a return on equity of 42.38%. The firm had revenue of $303.44 million for the quarter, compared to the consensus estimate of $300.68 million. During the same period in the prior year, the business posted $0.21 earnings per share. The business’s quarterly revenue was up 4.6% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.930-1.01 EPS. Sell-side analysts anticipate that Sotera Health Company will post 0.61 EPS for the current fiscal year.
Insider Buying and Selling at Sotera Health In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $15.27, for a total value of $152,700,000.00. Following the transaction, the director directly owned 12,735,301 shares of the company’s stock, valued at approximately $194,468,046.27. This trade represents a 43.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 47.55% of the company’s stock.
Analysts Set New Price Targets Several research analysts recently weighed in on the company. Zacks Research lowered Sotera Health from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Royal Bank Of Canada started coverage on Sotera Health in a research note on Thursday, January 8th. They set an “outperform” rating and a $24.00 target price on the stock. William Blair assumed coverage on Sotera Health in a report on Thursday, December 18th. They issued an “outperform” rating on the stock. Citigroup raised their price target on shares of Sotera Health from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Finally, Wells Fargo & Company downgraded shares of Sotera Health to an “overweight” rating in a research report on Thursday, January 8th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.43.
View Our Latest Report on SHC
Sotera Health Company Profile (Free Report)
Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.
Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.
Featured Articles Five stocks we like better than Sotera Health
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
Sotera Health Company (SHC - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
Therefore, the Zacks rating upgrade for Sotera Health basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Sotera Health imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for Sotera HealthThis company is expected to earn $0.96 per share for the fiscal year ending December 2026, which represents no year-over-year change.
Analysts have been steadily raising their estimates for Sotera Health. Over the past three months, the Zacks Consensus Estimate for the company has increased 1.4%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Sotera Health to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2026 before the market opens on Tuesday, May 5, 2026. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company’s operating and financial results.
A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health. A replay of the webcast will be available later in the day on May 5.
Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
Cwm LLC grew its position in shares of Sotera Health Company (NASDAQ:SHC – Free Report) by 1,235.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,330 shares of the company’s stock after purchasing an additional 64,139 shares during the quarter. Cwm LLC’s holdings in Sotera Health were worth $1,223,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Empowered Funds LLC grew its position in Sotera Health by 11.1% during the first quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock valued at $332,000 after buying an additional 2,845 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Sotera Health by 14.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after acquiring an additional 43,471 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after acquiring an additional 14,018 shares in the last quarter. Creative Planning boosted its stake in shares of Sotera Health by 15.3% during the 2nd quarter. Creative Planning now owns 20,186 shares of the company’s stock worth $224,000 after acquiring an additional 2,673 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Sotera Health by 4.2% during the 2nd quarter. Invesco Ltd. now owns 319,156 shares of the company’s stock valued at $3,549,000 after acquiring an additional 12,758 shares during the period. 91.03% of the stock is currently owned by institutional investors and hedge funds.
Sotera Health Price Performance Shares of SHC opened at $15.58 on Monday. The stock has a 50 day moving average price of $15.17 and a 200 day moving average price of $16.50. Sotera Health Company has a one year low of $10.68 and a one year high of $19.85. The company has a debt-to-equity ratio of 3.66, a quick ratio of 2.24 and a current ratio of 2.46. The stock has a market capitalization of $4.44 billion, a price-to-earnings ratio of 57.71 and a beta of 1.88.
Sotera Health (NASDAQ:SHC – Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 42.38% and a net margin of 6.70%.The company had revenue of $303.44 million for the quarter, compared to analyst estimates of $300.68 million. During the same quarter last year, the firm posted $0.21 EPS. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.930-1.01 EPS. Equities research analysts forecast that Sotera Health Company will post 0.88 earnings per share for the current fiscal year.
Insiders Place Their Bets In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $15.27, for a total transaction of $152,700,000.00. Following the transaction, the director directly owned 12,735,301 shares in the company, valued at approximately $194,468,046.27. The trade was a 43.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 15.36% of the company’s stock.
Analysts Set New Price Targets Several equities analysts recently weighed in on SHC shares. Citigroup lifted their price target on Sotera Health from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Barclays lowered their price target on Sotera Health from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Piper Sandler upgraded Sotera Health from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $17.00 to $24.00 in a research report on Friday, January 9th. Wells Fargo & Company downgraded Sotera Health to an “overweight” rating in a research note on Thursday, January 8th. Finally, Wall Street Zen lowered Sotera Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Sotera Health has a consensus rating of “Moderate Buy” and an average price target of $20.14.
Read Our Latest Analysis on SHC
About Sotera Health (Free Report)
Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.
Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.
Further Reading Five stocks we like better than Sotera Health
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEEvergreen Capital Management LLC Invests $456,000 in Teck Resources Ltd $TECK
NEXT HEADLINE »Cwm LLC Has $1.33 Million Stake in Janus Henderson Mortgage-Backed Securities ETF $JMBS
Alton Shader, CEO of Viant Medical®, to become CEO and join the Board of Directors, effective May 26, 2026Chairman and CEO Michael B. Petras, Jr. will serve as Executive Chairman of the Board of Directors CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced the appointment of Alton Shader to the role of Chief Executive Officer (“CEO”) of the Company, effective May 26, 2026, as part of a planned leadership transition. Mr. Shader will succeed Michael B. Petras, Jr., Chairman and CEO and will join the Sotera Health Board of Directors (the “Board”). Mr. Petras will serve as Executive Chairman of the Board and will work closely with Mr. Shader to ensure a seamless and successful leadership transition. He will remain engaged and be actively involved in investor relations, as well as commercial and litigation strategy, and will continue as a full-time employee for the foreseeable future.
Mr. Shader has served as CEO and director of Viant Medical, LLC (“Viant”), a global medical device design and manufacturing services provider, since 2019, and brings over 20 years of deep medical industry experience, a commercial-centric focus rooted in customer-first collaboration and innovation and a proven track record for driving growth across a range of companies. At Viant, he successfully led the company through a period of accelerated growth by expanding the global manufacturing footprint and strengthening its end-to-end capabilities through targeted acquisitions. During his tenure, Viant enhanced operational excellence, quality, and sustainability, positioning the company as a scaled, strategic partner to leading medical device original equipment manufacturers. Prior to Viant, Mr. Shader served as President of Hill-Rom’s global Front Line Care business, which included Welch Allyn, where he led the company’s fastest growing and most profitable global business. Prior to joining Hill-Rom, Mr. Shader held several senior positions at Baxter International Inc. in Europe and the United States including General Manager of its North America Renal business. Mr. Shader has a bachelor’s degree in economics and psychology from Claremont McKenna College and an M.B.A. from Stanford University.
Mr. Petras joined the Company as CEO in 2016 and provided outstanding strategic, operational and visionary leadership. Under his leadership, the Company grew revenue every single year, from $630 million in 2016 to $1.164 billion in 2025, and Adjusted EBITDA grew more than $300 million in that same period. Mr. Petras’ strategic vision drove the transformation from three autonomous businesses units to one Company, positioned under the Sotera Health brand with a unifying mission of Safeguarding Global Health®. Mr. Petras successfully led the organization through an initial public offering (IPO) with Sotera Health’s listing on the Nasdaq Stock Market in 2020. Mr. Petras will continue to provide guidance on strategic initiatives to support the Company’s longstanding track record of growth.
“The transition to Alton has been carefully planned to ensure Sotera Health’s continued success,” said Mr. Petras. “Alton’s strong commercial experience and track-record of driving growth in the healthcare industry makes him a great fit for Sotera Health. I look forward to supporting him and the leadership team in my new role as Executive Chairman to continue to grow and strengthen the Company.”
Vincent Petrella, who will remain in his position as Lead Independent Director of the Board, said “We are deeply grateful for Michael’s commitment to excellence for nearly a decade. The strength of Sotera Health’s position is a testament to his strategic and operational leadership. We are confident that Alton is the right leader to guide Sotera Health in its next chapter, and this transition underscores the strength and continuity of our leadership team.”
Mr. Shader added, “I am excited to join Sotera Health, a true leader in delivering critical services to its customers. It’s an honor to join the Company and to build on the successful track record that the team has established as we continue to deliver value well into the future.”
Earnings Webcast
Today, the Company will host a conference call and live webcast to discuss the Company’s operating highlights and financial results at 9:00 a.m. Eastern Daylight Time. A live webcast of the conference call will be accessible at this link or via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health, along with accompanying materials. A replay of the webcast will be archived on the Company’s website.
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
Updates on recent developments in matters relevant to investors can be found on the Investor Relations section of the Sotera Health website at Investor Relations | Sotera Health. For developments related to EO, updates can be found at Ethylene Oxide | Sotera Health.
INVESTOR RELATIONS CONTACT
Jason Peterson
Vice President Investor Relations [email protected]
MEDIA CONTACT
Kristin Gibbs
Chief Marketing Officer [email protected]
Q1 2026 net revenues increased 10.0%, or 6.5% on a constant currency basis, compared to Q1 2025Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025Q1 2026 Adjusted EBITDA(1) increased 10.5%, or 6.9% on a constant currency basisQ1 2026 Adjusted EPS(1) of $0.18, an increase of 29% per diluted shareCompany reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basisCompany announced planned CEO transition in a separate release today CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three months ended March 31, 2026.
“We delivered a strong start to the year, with solid revenue and Adjusted EBITDA growth while driving margin expansion,” said Chairman and Chief Executive Officer, Michael B. Petras, Jr. “Growth was driven by disciplined execution at Sterigenics and Nordion, and Nelson Labs came in as we outlined on our fourth-quarter 2025 earnings call. Based on our first-quarter performance, we are reaffirming our 2026 outlook and remain confident in our trajectory for the remainder of the year.”
Petras continued, “In addition to adding Rich Kyle to our Board of Directors in February, we are also excited to welcome Ken Krause, who joined our Board in March. Ken’s leadership and proven track record of creating shareholder value as a public company chief financial officer for over 10 years, and his extensive experience in strategy, finance and governance will be tremendous assets as we continue to grow.”
First-Quarter 2026 Highlights
(All comparisons are against first quarter of 2025, unless otherwise noted)
Delivered solid top- and bottom-line constant currency revenue growthExpanded Adjusted EBITDA marginsSterigenics: 6.1% constant currency revenue growth, driven by price and volume/mixNordion: 25.8% constant currency revenue growth; margin improvement of over 290 basis pointsNelson Labs: constant currency revenue and segment income margins as expectedNet cash provided by operating activities of $29 million, inclusive of a previously disclosed $34 million legal settlementAs of March 31, 2026, Net Leverage Ratio(1) of 3.2x and over $900 million in available liquidityAdded two independent directors to the Board of Directors, further strengthening Board skill setPublic float increased to approximately 90% of outstanding shares
_____________________________
(1) This is a non-GAAP financial measure used throughout this press release; please refer to the section “Non-GAAP Financial Measures” for explanations of our Non-GAAP financial measures and the schedules provided later in this release for reconciliations of reported GAAP to Non-GAAP financial measures.
First-Quarter Review by Business Segment
(All comparisons are against first quarter of 2025, unless otherwise noted)
Sterigenics
Sterigenics delivered solid first-quarter 2026 results, with net revenues up 9.7% to $186 million, or 6.1% on a constant currency basis. Segment income was $96 million, an increase of 9.6%.
Net revenues growth was driven by favorable pricing, foreign currency benefits and improved volume/mix. Segment income was also driven by these factors, partially offset by higher costs.
Nordion
Nordion first quarter net revenues were up 29.0% to $42 million, or 25.8% on a constant currency basis while segment income increased 36.1% to $24 million.
Net revenues growth was driven by volume/mix benefits due to timing of cobalt-60 harvest schedules, as well as foreign currency tailwinds and favorable pricing. Segment income and segment income margin growth were also driven by these factors, partially offset by inflation.
Nelson Labs
Nelson Labs first quarter net revenues were $52 million, a decrease of 0.7%, or 3.8% on a constant currency basis while segment income decreased 11.5% to $15 million.
Net revenues, segment income and segment income margin differences were driven by unfavorable volume/mix, partially offset by foreign currency benefits and favorable pricing.
Reaffirming 2026 Outlook
The 2026 outlook below, first provided on February 24, 2026, remains unchanged:
Net revenues in the range of $1.233 billion to $1.251 billion, representing constant currency growth of 5.0% to 6.5% and an estimated 100bps foreign currency benefitAdjusted EBITDA in the range of $632 million to $641 million, representing constant currency growth of 5.5% to 7.0% and an estimated 100bps foreign currency benefitInterest expense in the range of $135 million to $145 millionTax rate applicable to Adjusted Net Income(1) in the range of 27.0% to 29.0%Adjusted EPS in the range of $0.93 to $1.01A weighted-average fully diluted share count in the range of 289 million to 291 million sharesCapital expenditures in the range of $175 million to $225 million The Company does not provide a reconciliation for non-GAAP financial measures on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items without unreasonable effort. The Company cannot reconcile its expected Adjusted EBITDA, Adjusted Net Income Tax Rate, Adjusted Net Income and Adjusted EPS without unreasonable effort because certain items that impact net income, earnings per share and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time, including uncertainties caused by changes to the regulatory landscape, restructuring items and certain fair value measurements, all of which are potential adjustments for future earnings.
The outlook provided above contains a number of assumptions, including, among others, the Company’s current expectations regarding supply chain continuity, particularly for the supply of ethylene oxide (“EO”) and Cobalt-60, and the impact of inflationary trends including their impact on energy prices and the supply of labor. Our outlook is based on current plans and expectations and is subject to several known and unknown risks and uncertainties, including those set forth below under “Cautionary Note Regarding Forward-Looking Statements.”
Earnings Webcast
Sotera Health management will host a conference call and live webcast to discuss the Company’s operating highlights and financial results at 9:00 a.m. Eastern Daylight Time today. A live webcast of the conference call will be accessible at this link or via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health, along with accompanying materials. A replay of the webcast will be archived on the Company’s website.
Upcoming Investor Events
RBC Capital Markets Global Healthcare Conference at 3:05 p.m. Eastern Daylight Time, May 19, 2026Sotera Health 2026 Annual Meeting of Stockholders at 9:00 a.m. Eastern Daylight Time, May 21, 20262026 Jefferies Global Healthcare Conference at 2:35 p.m. Eastern Daylight Time, June 3, 2026Goldman Sachs 47th Annual Global Healthcare Conference at 11:20 a.m. Eastern Daylight Time, June 8, 2026 Cautionary Note Regarding Forward-Looking Statements
Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this release refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and reflects management’s expectations about future events and the Company’s operating plans and performance and speak only as of the date hereof. Forward-looking statements present our current forecasts and estimates of future events. These statements do not strictly relate to historical or current results and can be identified by words such as “anticipate,” “appear,” “assume,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “may,” “plan,” “project,” “seek,” “should,” “strategy,” “will” and other terms of similar meaning or import in connection with any discussion of future operating, financial or other performance. These forward-looking statements are subject to risks, uncertainties and other factors and actual results may differ materially from those results projected in the statements. These forward-looking statements are subject to various risks, uncertainties and assumptions relating to our operations, financial results, financial condition, business, prospects, growth strategy and liquidity. These risks and uncertainties include, but are not limited to, a disruption in the availability or supply of, or increases in the price of, EO, Co-60 or our other direct materials, services and supplies, including as a result of geopolitical instability and/or sanctions against Russia by the United States, Canada, the United Kingdom and/or the European Union, or sanctions by Russia against those countries; fluctuations in foreign currency exchange rates; evolving changes in environmental, health and safety regulations; health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60; the impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions and releases of EO from our current and former EO sterilization facilities and the possibility that additional claims will be made in the future; allegations of our failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm; compliance with the extensive regulatory requirements to which we are subject, the related costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals; adverse changes in industry trends; competition we face; market conditions and changes, including inflationary trends and the impact of tariffs, that impact our long-term supply contracts with variable price clauses and increase our cost of revenues; business continuity hazards, including supply chain disruptions, federal government shutdowns, and other risks associated with our operations; the risks of doing business internationally, including global and regional economic and political instability and compliance with various applicable laws and potentially inconsistent laws and regulations in multiple jurisdictions; our ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for our leased facilities; our ability to attract and retain qualified employees; severe health events or environmental events; cybersecurity incidents, unauthorized data disclosures, and our dependence on information technology systems; the risks associated with the introduction of artificial intelligence technology; an inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions into our business successfully; our ability to maintain effective internal control over financial reporting; our reliance on intellectual property rights to maintain our competitive position and the risk of claims from third parties that we have infringed or misappropriated, or are infringing or misappropriating, their intellectual property rights; our ability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions and any ineffective compliance efforts with such laws and regulations; our ability to generate profitability in future periods; impairment charges on our goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives; the effects of unionization efforts and labor regulations in countries in which we operate; adverse changes to our tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations; our significant degree of leverage and how this leverage could adversely affect our ability to raise additional capital, limit our ability to react to challenges facing our Company or broader changes in our industry or the economy, limit our flexibility in operating our business through restrictions contained in our debt agreements and/or prevent us from meeting our obligations under our existing and future agreements governing our indebtedness; and the influence that certain investment funds and entities affiliated with Warburg Pincus and GTCR continue to have over us. For additional discussion of these risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, such as its Annual Report on Form 10-K and quarterly reports. We do not undertake any obligation to publicly update or revise these forward-looking statements, except as otherwise required by law.
Non-GAAP Financial Measures
To supplement our consolidated financial statements presented in accordance with GAAP, we consider Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Tax Rate, Adjusted Net Income, Adjusted EPS, Segment income margin, Net Debt and Net Leverage Ratio and constant currency, financial measures that are not based on any standardized methodology prescribed by GAAP.
We define Adjusted Net Income as net income (loss) before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period.We define Adjusted EBITDA as Adjusted Net Income before interest expense, depreciation (including depreciation of Cobalt-60 used in our operations) and income tax provision applicable to Adjusted Net Income.Adjusted EBITDA margin is equal to Adjusted EBITDA divided by net revenues.Segment income margin is equal to segment income divided by net segment revenues.We define Adjusted EPS as Adjusted Net Income divided by the weighted average number of diluted shares outstanding.Our Net Debt is equal to our total debt, plus unamortized debt issuance costs and debt discounts, less cash and cash equivalents.Our Net Leverage Ratio is equal to Net Debt divided by Adjusted EBITDA. Constant currency is a non-GAAP financial measure we use to assess performance excluding the impact of foreign currency exchange rate changes. We calculate constant currency net revenues by translating prior year net revenues in local currency at the average exchange rates applicable for the current period. The translated results are then used to determine year-over-year percentage increases or decreases. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign currency exchange rates. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.
We use these non-GAAP financial measures as the principal measures of our operating performance. Management believes these measures allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations. We believe that these measures are useful to our investors because they provide a more complete understanding of the factors and trends affecting our business than could be obtained without these measures and their disclosure. In addition, we believe these measures will assist investors in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. Our management also uses these measurements in their financial analysis and operational decision-making and Adjusted EBITDA serves as the key metric for the attainment of our primary annual incentive program. These measures may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
Updates on recent developments in matters relevant to investors can be found on the Investor Relations section of the Sotera Health website at Investor Relations | Sotera Health. For developments related to EO, updates can be found at Ethylene Oxide | Sotera Health.
INVESTOR RELATIONS CONTACT
Jason Peterson
Vice President Investor Relations [email protected]
MEDIA CONTACT
Kristin Gibbs
Chief Marketing Officer [email protected]
Source: Sotera Health Company
Sotera Health Company
Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited) Three Months Ended March 31, 2026 2025 Revenues: Service $241,608 $223,940 Product 38,437 30,583 Total net revenues 280,045 254,523 Cost of revenues: Service 118,828 107,629 Product 14,148 11,462 Total cost of revenues 132,976 119,091 Gross profit 147,069 135,432 Selling, general and administrative expenses 68,211 63,061 Amortization of intangible assets 3,031 15,327 Illinois EO litigation settlement — 30,943 Interest expense, net 34,745 40,876 Foreign exchange (gain) loss (571) 289 Other income, net (960) (241)Income (Loss) before income taxes 42,613 (14,823)Provision (Benefit) for income taxes 16,024 (1,563)Net income (loss) $26,589 $(13,260) Earnings (Loss) per share: Basic $0.09 $(0.05)Diluted 0.09 (0.05)Weighted average number of shares outstanding: Basic 284,887 283,558 Diluted 287,622 283,558 Sotera Health Company
Segment Data
(in thousands)
(unaudited) Three Months Ended March 31, 2026 2025 Segment revenues: Sterigenics $186,135 $169,684 Nordion 42,009 32,557 Nelson Labs 51,901 52,282 Total net revenues $280,045 $254,523 Segment income: Sterigenics $96,414 $88,004 Nordion 23,711 17,422 Nelson Labs 14,528 16,413 Total segment income 134,653 121,839 Less adjustments: Interest expense, net 34,745 40,876 Depreciation and amortization(a) 30,744 40,734 Share-based compensation(b) 14,442 7,269 Loss on foreign currency and derivatives not designated as hedging instruments, net(c) 624 1,891 Business optimization expenses(d) 957 2,047 Professional services relating to EO sterilization facilities(e) 9,855 12,328 Illinois EO litigation settlement(f) — 30,943 Accretion of asset retirement obligations(g) 673 574 Consolidated income (loss) before income taxes $42,613 $(14,823)
(a) Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.
(b) Represents share-based compensation expense to employees and Non-Employee Directors.
(c) Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.
(d) Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with secondary offerings and shareholder engagement.
(e) Represents litigation and other professional fees associated with our EO sterilization facilities.
(f) Represents the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025.
(g) Represents non-cash accretion of asset retirement obligations (“ARO”) related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset. Sotera Health Company
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited) As of March 31,
As of December 31,
2026 2025 Assets Current assets: Cash and cash equivalents $315,945 $346,456 Accounts receivable, net 137,256 139,329 Inventories, net 57,494 54,375 Other current assets 75,276 73,250 Total current assets 585,971 613,410 Property, plant, and equipment, net 1,143,452 1,130,564 Operating lease assets 32,896 33,393 Other intangible assets, net 279,357 288,227 Goodwill 1,097,634 1,103,232 Other assets 96,588 94,364 Total assets $3,235,898 $3,263,190 Liabilities and equity Total current liabilities $207,804 $249,584 Long-term debt, less current portion 2,124,327 2,126,724 Other noncurrent liabilities 206,220 209,772 Deferred income taxes 75,042 71,075 Total liabilities 2,613,393 2,657,155 Total equity 622,505 606,035 Total liabilities and equity $3,235,898 $3,263,190 Sotera Health Company
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Three Months Ended March 31, 2026 2025 Operating activities: Net income (loss) $26,589 $(13,260)Adjustments to reconcile net income (loss) to net cash provided by operating activities: Non-cash items 48,950 39,310 Changes in operating assets and liabilities (46,104) 29,471 Net cash provided by operating activities 29,435 55,521 Investing activities: Purchases of property, plant and equipment (46,166) (19,918)Other investing activities 1,038 37 Net cash used in investing activities (45,128) (19,881)Financing activities: Payment on long-term borrowings (3,558) (3,773)Payments of debt issuance costs — (10)Shares withheld for employee taxes on equity awards (8,802) (3,600)Other financing activities (419) (704)Net cash used in financing activities (12,779) (8,087)Effect of exchange rate changes on cash and cash equivalents (2,039) (337)Net (decrease) increase in cash and cash equivalents, including restricted cash (30,511) 27,216 Cash and cash equivalents, including restricted cash, at beginning of period 346,456 278,865 Cash and cash equivalents, including restricted cash, at end of period $315,945 $306,081 Supplemental disclosures of cash flow information: Cash paid during the period for interest $36,546 $47,416 Cash paid during the period for income taxes, net of tax refunds received 9,200 12,215 Purchases of property, plant and equipment included in accounts payable 20,689 13,042 Sotera Health Company
Non-GAAP Financial Measures
(in thousands, except per share amounts)
(unaudited)
Three Months Ended March 31, 2026 2025 Net income (loss) $26,589 $(13,260)Amortization of intangible assets 5,602 18,674 Share-based compensation(a) 14,442 7,269 Loss on foreign currency and derivatives not designated as hedging instruments, net(b) 624 1,891 Business optimization expenses(c) 957 2,047 Professional services relating to EO sterilization facilities(d) 9,855 12,328 Illinois EO litigation settlement(e) — 30,943 Accretion of asset retirement obligations(f) 673 574 Income tax benefit associated with pre-tax adjustments(g) (6,376) (21,422)Adjusted Net Income 52,366 39,044 Interest expense, net 34,745 40,876 Depreciation(h) 25,142 22,060 Income tax provision applicable to Adjusted Net Income(i) 22,400 19,859 Adjusted EBITDA(j) $134,653 $121,839 Net Revenues $280,045 $254,523 Adjusted EBITDA Margin 48.1% 47.9%Weighted average number of shares outstanding Basic 284,887 283,558 Diluted(k) 287,622 285,714 Earnings (Loss) per share Basic $0.09 $(0.05)Diluted 0.09 (0.05)Adjusted earnings per share Basic $0.18 $0.14 Diluted 0.18 0.14
(a) Represents share-based compensation expense to employees and Non-Employee Directors.
(b) Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.
(c) Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with secondary offerings and shareholder engagement.
(d) Represents litigation and other professional fees associated with our EO sterilization facilities.
(e) Represents the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025.
(f) Represents non-cash accretion of ARO related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.
(g) Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities and unusual items from our presentation of adjusted net income.
(h) Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.
(i) Represents the difference between the income tax provision as determined under U.S. GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (g).
(j) $26.3 million and $24.2 million of the adjustments for the three months ended March 31, 2026 and 2025, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.
(k) For the three months ended March 31, 2025, the diluted weighted average shares outstanding presented in this table reflects the amount that would be reported under U.S. GAAP if the Company were to have net income in the three months ended March 31, 2025. Sotera Health Company
Non-GAAP Financial Measures
(in thousands, except Net Leverage)
(unaudited) As of March 31, As of December 31, 2026 2025 Current portion of long-term debt $13,983 $13,973 Long-term debt 2,124,327 2,126,724 Current portion of finance leases 3,577 3,465 Finance leases less current portion 93,201 93,835 Total Debt $2,235,088 $2,237,997 Less: cash and cash equivalents (314,147) (344,621)Net Debt $1,920,941 $1,893,376 Adjusted EBITDA(a) $606,615 $593,801 Net Leverage 3.2
x
3.2
x
(a) Represents adjusted EBITDA for the twelve months ended March 31, 2026 and December 31, 2025, respectively. Refer to the reconciliation of net income (the most comparable GAAP measure) to Adjusted EBITDA on the following page. Sotera Health Company
Non-GAAP Financial Measures
(in thousands)
(unaudited)
Twelve months ended March 31, 2026 December 31, 2025Net income $117,798 $77,949 Amortization of intangible assets 28,726 41,798 Share-based compensation(a) 38,241 31,068 Loss on refinancing of debt(b) 1,462 1,462 (Gain) Loss on foreign currency and derivatives not designated as hedging instruments, net(c) (1,209) 58 Business optimization expenses(d) 6,978 8,068 Professional services relating to EO sterilization facilities(e) 43,752 46,225 Illinois EO litigation settlements(f) 34,000 64,943 Accretion of asset retirement obligations(g) 2,420 2,321 Income tax benefit associated with pre-tax adjustments(h) (13,432) (28,478)Adjusted Net Income 258,736 245,414 Interest expense, net 149,591 155,722 Depreciation(i) 97,712 94,630 Income tax provision applicable to Adjusted Net Income(j) 100,576 98,035 Adjusted EBITDA(k) $606,615 $593,801 Net Revenues $1,189,139 $1,163,617 Adjusted EBITDA Margin 51.0% 51.0%
(a) Represents share-based compensation expense to employees and Non-Employee Directors.
(b) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the refinancing activity for the Term Loans, the Secured Notes and the Revolving Credit Facility.
(c) Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.
(d) Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with secondary offerings and shareholder engagement.
(e) Represents litigation and other professional fees associated with our EO sterilization facilities.
(f) Represents (i) the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025 and (ii) the cost to settle 129 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on July 23, 2025.
(g) Represents non-cash accretion of ARO related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.
(h) Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities and unusual items from our presentation of adjusted net income.
(i) Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.
(j) Represents the difference between income tax provision or benefit as determined under U.S. GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (h).
(k) $102.0 million and $99.9 million of the adjustments for the twelve months ended March 31, 2026 and December 31, 2025, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.
Sotera Health Company (SHC - Free Report) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +3.87%. A quarter ago, it was expected that this company would post earnings of $0.24 per share when it actually produced earnings of $0.26, delivering a surprise of +8.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Sotera Health, which belongs to the Zacks Medical Services industry, posted revenues of $280.05 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.97%. This compares to year-ago revenues of $254.52 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Sotera Health shares have lost about 12.8% since the beginning of the year versus the S&P 500's gain of 5.2%.
What's Next for Sotera Health?While Sotera Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Sotera Health was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.25 on $315.38 million in revenues for the coming quarter and $0.96 on $1.24 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Sonida Senior Living (SNDA - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.
This operator of senior living communities is expected to post quarterly loss of $1.67 per share in its upcoming report, which represents a year-over-year change of -116.9%. The consensus EPS estimate for the quarter has been revised 30.9% higher over the last 30 days to the current level.
Sonida Senior Living's revenues are expected to be $87.94 million, up 9.5% from the year-ago quarter.
Sotera Health Company (SHC - Free Report) reported $280.05 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 10%. EPS of $0.18 for the same period compares to $0.14 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $271.98 million, representing a surprise of +2.97%. The company delivered an EPS surprise of +3.87%, with the consensus EPS estimate being $0.17.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Sotera Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Revenues- Sterigenics: $186.14 million compared to the $183.41 million average estimate based on two analysts. The reported number represents a change of +9.7% year over year.Net Revenues- Nelson Labs: $51.9 million compared to the $51.84 million average estimate based on two analysts. The reported number represents a change of -0.7% year over year.Net Revenues- Nordion: $42.01 million versus the two-analyst average estimate of $38.17 million. The reported number represents a year-over-year change of +29%.View all Key Company Metrics for Sotera Health here>>>
Shares of Sotera Health have returned +3.5% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Sotera Health (SHC 0.55%) offers sterilization and lab testing for healthcare and life sciences clients, supporting global regulatory compliance.
Broyhill Asset Management, LLC disclosed a buy of Sotera Health, adding 252,588 shares in the first quarter. The estimated transaction value, based on average quarterly pricing, was $4.19 million, according to the firm’s SEC filing dated May 06, 2026.
What happenedAccording to an SEC filing dated May 06, 2026, Broyhill Asset Management, LLC bought 252,588 additional shares of Sotera Health (SHC 0.55%) in the first quarter of 2026. The estimated value of this transaction was $4.19 million, calculated using the mean unadjusted close for the quarter. The quarter-end value of the SHC position rose by $3.53 million, reflecting both the share increase and underlying stock price appreciation.
What else to knowThis was a buy transaction, bringing the SHC position to 3.73% of Broyhill’s 13F reportable assets under management as of March 31, 2026.Top holdings after the filing:NASDAQ: SHY: $6.75 million (6.23% of AUM)NYSE: IQV: $5.58 million (5.58% of AUM)NYSE: VVV: $5.18 million (4.79% of AUM)NYSE: RTO: $4.34 million (4.01% of AUM)NYSEMKT: LQD: $4.09 million (3.78% of AUM)As of May 5, 2026, Sotera Health shares were priced at $15.33, up 18.7% over the prior year, but underperformed the S&P 500 by 9.82 percentage points.The company’s trailing-12-month revenue was $1.19 billion, with net income of $117.80 million and a five-year revenue CAGR of 7.3%.Sotera Health’s forward P/E is 15.17 and EV/EBITDA stands at 14.12 as of March 31, 2026. The stock was 20.1% below its 52-week high as of May 6, 2026.Company OverviewMetricValueRevenue (TTM)$1.19 billionNet Income (TTM)$117.80 millionPrice (as of market close 2026-05-05)$15.33One-Year Price Change18.65%Company SnapshotOffers sterilization services (gamma, electron beam, EO processing), microbiological and analytical chemistry testing, and advisory solutions for regulatory and quality needs.Generates revenue primarily through service contracts with medical device, pharmaceutical, food, and industrial clients, leveraging specialized facilities and scientific expertise.Main customers include medical device manufacturers, pharmaceutical companies, and organizations in the food and agricultural sectors seeking compliance and safety assurance.Sotera Health is a leading provider of mission-critical sterilization and lab testing services, supporting the safety and regulatory compliance of healthcare and life sciences industries. The company operates a global platform with advanced technologies and a diversified client base, enabling consistent revenue generation and resilience. Its integrated service offerings and regulatory expertise position it as a trusted partner for organizations requiring high standards of product safety and quality.
What this transaction means for investorsBroyhill’s recent purchase of Sotera Health’s shares may indicate this institution is taking a chance on a company it perceives as being temporarily undervalued. Broyhill had a small stake in the company before the transaction, so it was already on their radar.
Sotera has faced recent regulatory and legal challenges, making it somewhat of a contrarian investment. The market may be overly pessimistic about the company, though, given what it has going for it. It provides an essential service for healthcare providers and labs, which has steady demand and high barriers to entry. So it’s reasonable to believe it may get past its current concerns and thrive.
It’s important to note, however, that an institution like Broyhill has a large, balanced portfolio and can afford to take chances like this. Its top five holdings reflect a conservative approach, with exposure to low-risk investments. Investors with a well-balanced, diversified portfolio and a contrarian streak might consider Sotera or other similar companies within the sector.
Pamela Kock has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iqvia Holdings. The Motley Fool recommends Rentokil Initial Plc. The Motley Fool has a disclosure policy.
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 31,838,253 shares of its common stock, par value $0.01 per share. All 31,838,253 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registration Rights Agreement.
Goldman Sachs & Co. LLC is acting as the underwriter for the Offering.
The Offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the Offering may be obtained, when available, from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526 or by email at [email protected].
A registration statement relating to these securities was filed with the Securities and Exchange Commission on February 27, 2024, and became effective automatically.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-looking Statements:
Statements in this press release regarding the Company that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Certain of these risks and uncertainties are described in the Company’s registration statement on Form S-3 filed with the SEC, including under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements,” under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K. Forward-looking statements made in this release speak only as of the date of this release, and the Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances, except as required by law.
About Sotera Health:
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
INVESTOR RELATIONS CONTACT:
Jason Peterson
Vice President, Investor Relations, Sotera Health [email protected]
MEDIA CONTACT:
Kristin Gibbs
Chief Marketing Officer, Sotera Health [email protected]
Amdocs (NASDAQ:DOX – Get Free Report) and Fujitsu (OTCMKTS:FJTSY – Get Free Report) are both computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.
Earnings & Valuation This table compares Amdocs and Fujitsu”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amdocs $4.58 billion 1.56 $564.70 million $5.17 12.77 Fujitsu $23.31 billion 1.54 $1.45 billion $0.45 45.47 Fujitsu has higher revenue and earnings than Amdocs. Amdocs is trading at a lower price-to-earnings ratio than Fujitsu, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk Amdocs has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Fujitsu has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
Analyst Recommendations This is a breakdown of recent recommendations and price targets for Amdocs and Fujitsu, as reported by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amdocs 0 2 3 0 2.60 Fujitsu 0 2 0 0 2.00 Amdocs currently has a consensus price target of $92.33, suggesting a potential upside of 39.81%. Given Amdocs’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Amdocs is more favorable than Fujitsu.
Profitability This table compares Amdocs and Fujitsu’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Amdocs 12.47% 20.19% 11.23% Fujitsu N/A N/A N/A Insider & Institutional Ownership 92.0% of Amdocs shares are held by institutional investors. Comparatively, 0.1% of Fujitsu shares are held by institutional investors. 15.4% of Amdocs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Dividends Amdocs pays an annual dividend of $2.27 per share and has a dividend yield of 3.4%. Fujitsu pays an annual dividend of $0.12 per share and has a dividend yield of 0.6%. Amdocs pays out 43.9% of its earnings in the form of a dividend. Fujitsu pays out 26.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amdocs has raised its dividend for 14 consecutive years. Amdocs is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Summary Amdocs beats Fujitsu on 12 of the 17 factors compared between the two stocks.
About Amdocs (Get Free Report)
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers. It also offers AI-powered, cloud-native, and home operating systems; data intelligence solutions and applications; end-to-end application development and maintenance services; and ongoing maintenance services. In addition, the company provides a line of services designed for various stages of a service provider’s lifecycle includes consulting, delivery, quality engineering, operations, systems integration, network services, experience-driven services, data, cloud, and content services; managed services comprising application development, modernization and maintenance, IT and infrastructure services, testing and professional services that are designed to assist customers in the selection, implementation, operation, management, and maintenance of IT systems. It serves to the communications, entertainment, and media industry service providers, as well as mobile virtual network operators. Amdocs Limited was founded in 1988 and is headquartered in Saint Louis, Missouri.
About Fujitsu (Get Free Report)
Fujitsu Limited operates as an information and communication technology company in Japan and internationally. The company operates through three segments: Technology Solutions, Ubiquitous Solutions, and Device Solutions. The company offers multi cloud and hybrid IT services; assessment and consultative services; SAP landscape transformation services; new workplace; datacentre products comprising integrated systems, storage solutions, servers, network switches, and infrastructure management; workplace products including notebooks, tablet PC’s, desktop PC’s, workstations, thin clients, displays, and peripheral devices; consumption based IT services; installation and implementation services; and hardware, software, and infrastructure support services, as well as electronic devices, air conditioning products, and network solutions. It also provides cyber security solutions, including cyber security consulting, managed security servies, and security operation and advanced threat centers; internet of things, artificial intelligence platform and solutions; and software products comprising FUJITSU Software Infrastructure Manager and FUJITSU Software ServerView Suite. Further, the company offers electronic components, such as semiconductor packages and batteries. It serves automotive, manufacturing, retail, financial services, transport, telecommunications, healthcare, and energy and utilities industries; the public sectors; and services providers. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.
Investors with an interest in Computers - IT Services stocks have likely encountered both Amdocs (DOX - Free Report) and Infosys (INFY - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Currently, Amdocs has a Zacks Rank of #2 (Buy), while Infosys has a Zacks Rank of #4 (Sell). This means that DOX's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one factor that value investors are interested in.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
DOX currently has a forward P/E ratio of 8.87, while INFY has a forward P/E of 16.57. We also note that DOX has a PEG ratio of 1.04. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. INFY currently has a PEG ratio of 1.79.
Another notable valuation metric for DOX is its P/B ratio of 2.06. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, INFY has a P/B of 6.1.
These are just a few of the metrics contributing to DOX's Value grade of A and INFY's Value grade of C.
DOX stands above INFY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that DOX is the superior value option right now.
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
One company value investors might notice is Amdocs (DOX - Free Report) . DOX is currently holding a Zacks Rank #2 (Buy) and a Value grade of A. The stock is trading with P/E ratio of 11.05 right now. For comparison, its industry sports an average P/E of 17.62. Over the past 52 weeks, DOX's Forward P/E has been as high as 13.67 and as low as 11.05, with a median of 12.19.
Investors will also notice that DOX has a PEG ratio of 1.25. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DOX's industry currently sports an average PEG of 2.28. Over the last 12 months, DOX's PEG has been as high as 1.38 and as low as 1.13, with a median of 1.26.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Amdocs is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, DOX feels like a great value stock at the moment.
Amdocs is rated a Buy, offering strong free cash flow, resilient fundamentals, and attractive valuation near 52-week lows. DOX boasts a $4.25B backlog, robust managed services, and recent acquisitions (MATRIXX, Profinit) driving half of projected 2026 revenue growth. Free cash flow yield stands at 10%, with 90% earnings conversion, a rising 3.5% dividend, and $840M in buyback authorization through 2025.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Amdocs (DOX - Free Report) Amdocs Limited is one of the leading providers of customer care, billing and order management systems for communications and Internet services.
DOX is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9; value investors should take notice.
For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $7.44 per share. DOX boasts an average earnings surprise of +2.2%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, DOX should be on investors' short list.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Amdocs (DOX - Free Report) Amdocs Limited is one of the leading providers of customer care, billing and order management systems for communications and Internet services.
DOX is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.
Additionally, the company could be a top pick for growth investors. DOX has a Growth Style Score of B, forecasting year-over-year earnings growth of 6.4% for the current fiscal year.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.01 to $7.44 per share. DOX boasts an average earnings surprise of +2.2%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DOX should be on investors' short list.
Investors with an interest in Computers - IT Services stocks have likely encountered both Amdocs (DOX) and Jack Henry (JKHY). But which of these two stocks offers value investors a better bang for their buck right now?
Earnings Revenue of $1.17 Billion, up 3.9% YoY as Reported and up 2.2% YoY in Constant Currency(1)
Expects Fiscal 2026 Revenue Growth Outlook of 2.6%-4.6% YoY as Reported
Reiterates Midpoint of Fiscal 2026 Revenue Growth Outlook in Constant Currency(1) while Tightening Expected Range to 2.0%-4.0% YoY
Announces Retirement of Long-Serving CFO and Appointment of Internal CFO Successor
Second Quarter Fiscal 2026 Highlights
(All comparisons are against same quarter of the prior year, unless otherwise stated)
Revenue of $1,172 million, up 3.9% as reported and up 2.2% in constant currency(1); revenue was above the midpoint of the $1,150-$1,190 million guidance range and includes a positive impact from foreign currency movements of approximately $2 million relative to our guidance assumptions
Revenue of $754 million in North America, up 2.2%; record revenue of $192 million in Europe, up 6.2%; revenue of $226 million in Rest of World, up 8.0%
Managed services revenue of $759 million, equivalent to approximately 65% of total revenue and up 1.6%
GAAP diluted EPS of $1.28, above the midpoint of the guidance range of $1.22-$1.30
Non-GAAP diluted EPS of $1.78, above the midpoint of the guidance range of $1.73-$1.79
GAAP operating income of $183 million; GAAP operating margin of 15.6%, down 190 basis points compared to last year’s second quarter and 230 basis points sequentially, mainly due to costs related to leadership transition as well as benefit from changes in certain acquisitions related liabilities measured at fair value in the first fiscal quarter
Non-GAAP operating income of $252 million; non-GAAP operating margin of 21.5%, up 20 basis points as compared to last year’s second fiscal quarter and down 10 basis points sequentially
Free cash flow of $80 million, comprised of cash flow from operations of $102 million, including $17 million of restructuring payments, less $21 million in net capital expenditures(2); excluding restructuring payments, free cash flow was $97 million; reiterates full year fiscal 2026 free cash outlook of $710 million to $730 million, excluding restructuring payments
Repurchased $138 million of ordinary shares during the second fiscal quarter
Twelve-month backlog of $4.28 billion, up $30 million sequentially and up 2.6%
Amdocs Limited (the “Company” or “Amdocs”) announced today that Tamar Rapaport-Dagim, Chief Financial Officer and Chief Operating Officer, has decided to retire from the Company following a distinguished career spanning over two decades. Tal Rozenfeld, currently General Manager Head of Finance, has been appointed Chief Financial Officer, effective June 1st, 2026. Tamar will continue to complete the transition process to help ensure a seamless handover of responsibilities.
(1) Revenue on a constant currency basis assumes exchange rates in the current period were unchanged from the prior period
(2)Please refer to the Selected Financial Metrics tables below (figures may not sum because of rounding)
JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs Limited (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today reported operating results for the three months ended March 31, 2026.
"I'm excited to be leading Amdocs forward in the agentic era, as our vision is to become the primary partner of choice to turn the agentic opportunity into reality for our customers. We believe Amdocs is uniquely positioned to lead due to our deep industry knowledge and telco domain expertise, engineering and innovation pedigree, mission critical systems transformation leadership and our outcome-based business model. To realize our vision, we are aiming to move towards an agentic and automated portfolio, tailor agentic customer roadmaps, leverage strategic partnerships, and internally transform the way we operate. While we are continuing to refine our strategy, we are already seeing initial commercial engagements with the launch of aOS- Amdocs' agentic operating system for telco.
We are building this strategy on our strong business foundations, as demonstrated by solid Q2 results which show healthy sales, strong customer relationships and consistent operating execution," said Shimie Hortig, president and chief executive officer of Amdocs Management Limited.
"Project delivery continued as a defining strength for Amdocs this quarter, as reflected by many production milestones achieved for AT&T, Vodafone Germany and other flagship customers worldwide. Profitability improved year-over-year, demonstrating our continued focus on operational excellence and automation, and we generated healthy free cash flow of which we returned more than 100% to shareholders though share repurchases and dividend payments," said Tamar Rapaport-Dagim, chief financial officer and chief operating officer of Amdocs Management Limited.
Hortig continued, "I'm pleased with our financial and operational progress for the fiscal year to date, and while we are closely monitoring macroeconomic developments and customer spending behavior in the current climate, we are on track to achieve our fiscal 2026 financial guidance."
Hortig concluded, "On behalf of the Board and the entire leadership team, I want to thank Tamar for her exceptional leadership, partnership and dedication over the past 22 years. Throughout her tenure, Tamar has played a critical role in strengthening our financial foundation, leading operational excellence, supporting our strategic growth and helping position the company for long-term success. We are deeply grateful for her many contributions and wish her the very best. We are very pleased to appoint Tal Rozenfeld as our next Chief Financial Officer. Tal brings deep financial expertise, strong operational and business knowledge and a proven track record of leadership. Tal has been an important part of our finance and leadership team, and we are confident he will play a key role in driving the next phase of Amdocs' growth and execution."
Revenue
(All comparisons are against same quarter as the prior year, unless otherwise stated )
In millions
Three months ended
March 31, 2026
Actual
Guidance
Revenue
$1,172
$ 1,150 - $1,190
Revenue Growth, as reported
3.9%
Revenue Growth, constant currency(1)
2.2%
Revenue for the second fiscal quarter of 2026 was above the midpoint of Amdocs' guidance and includes positive impact from foreign currency movement of $2 million compared to our guidance assumptions
Revenue for the second fiscal quarter includes a positive impact from foreign currency movements of $19 million relative to the second quarter of fiscal 2025 and a positive impact from foreign currency movements of $3 million relative to the first quarter of fiscal 2026
Net Income and Earnings Per Share
In thousands, except per share data
Three months ended
March 31,
2026
2025
GAAP Measures
Net Income
$138,772
$164,001
Net Income attributable to Amdocs Limited
$137,815
$163,243
Diluted earnings per share
$1.28
$1.45
Non-GAAP Measures
Non-GAAP Net Income
$192,501
$201,017
Non-GAAP Net Income attributable to Amdocs Limited
$191,544
$200,259
Non-GAAP Diluted earnings per share
$1.78
$1.78
Non-GAAP net income excludes amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition related liabilities measured at fair value, equity-based compensation expenses, restructuring charges, and other, net of related tax effects. For further details of the reconciliation of selected financial metrics from GAAP to Non-GAAP, please refer to the tables below
Capital Allocation & Liquidity
Quarterly Cash Dividend Program: On May 13, 2026, the Board approved the Company's next quarterly cash dividend payment at the rate of $0.569 per share, and set June 30, 2026 as the record date for determining the shareholders entitled to receive the dividend, which will be payable on July 31, 2026
Share Repurchase Activity: Repurchased $138 million of ordinary shares during the second quarter of fiscal 2026
Commercial Paper Program: In March 2026, the Company established a commercial paper program, supported by the Revolving Credit Facility under which it may issue unsecured commercial paper up to a total of $800 million outstanding at any time, with maturities of up to 397 days from the date of issue. The net proceeds from the issuance of commercial paper are expected to be used for general corporate purposes. As of March 31, 2026, there was no outstanding borrowing amount under the commercial paper program
Revolving Credit Facility: In March 2026, the Revolving Credit Facility was amended to increase the amount from $500 million to an aggregate amount of $800 million
Twelve-month Backlog
Twelve-month backlog was $4.28 billion at the end of the second quarter of fiscal 2026, up approximately 2.6% as compared to last year's second fiscal quarter. Twelve-month backlog includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities.
Third Quarter Fiscal Year 2026 Outlook
In millions, except per share data
Q3 - 2026
Revenue
$ 1,155-$1,195
GAAP Diluted earnings per share
$ 1.39-$1.47
Non-GAAP Diluted earnings per share
$ 1.81-$1.87
Third quarter revenue guidance assumes a negative $1 million sequential impact from foreign currency fluctuations as compared to the second quarter of fiscal 2026
GAAP diluted EPS guidance does not include the impact of future restructuring charges
Third quarter non-GAAP diluted EPS guidance excludes primarily equity-based compensation expense of approximately $0.22-$0.24 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.16 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects
Full Year Fiscal 2026 Outlook
FY 2026 - Year-over -Year growth
Current guidance
Previous guidance
Revenue Growth, as reported
2.6%-4.6%
1.5%-5.5%
Revenue Growth, constant currency (1)
2.0%-4.0%
1.0%-5.0%
GAAP Diluted earnings per share
12.0%-15.0%
10.0%-17.0%
Non-GAAP Diluted earnings per share
5.0%-7.0%
4.0%-8.0%
FY 2026, in millions
Current guidance
Previous guidance
Free Cash Flow (2)
$ 710-$730
$ 710-$730
Full year fiscal 2026 revenue guidance incorporates an expected positive impact from foreign currency fluctuations of approximately 0.6% year-over-year compared with a positive impact of 0.5% year-over-year previously, and includes some inorganic contribution
GAAP diluted EPS guidance does not include the impact of future restructuring charges
Non-GAAP diluted earnings per share growth excludes primarily equity-based compensation expense of approximately $0.97-$1.01 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.58 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects
Non-GAAP operating margin is anticipated to be within a range of 21.3% to 21.9% for the full year fiscal 2026
Non-GAAP operating margin is comprised of GAAP operating margin, excluding amortization of purchased intangible assets and other, equity-based compensation expense, restructuring charges, and changes in certain acquisitions related liabilities measured at fair value
Non-GAAP effective tax rate is anticipated to be within a range of 16% to 19% for the full year fiscal 2026
Reiterates full year fiscal 2026 free cash flow(2) of $710 million to $730 million, excluding payments related to restructuring charges; free cash flow(2) is comprised of cash flow from operations, less net capital expenditures
The forward-looking statements regarding our third fiscal quarter 2026 and full year fiscal 2026 guidance take into consideration the Company's current expectations regarding macroeconomic, geopolitical and industry specific risks and various uncertainties and certain assumptions, some of which we will discuss on our earnings conference call. However, we note that market dynamics continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from certain geopolitical events, the current inflationary environment, changes to trade policies including tariffs and trade restrictions and the resulting impact on economic activities (as our outlook assumes current economic conditions do not deteriorate significantly due to trade policy or other macro factors), global or regional events, and the prevailing level of macro-economic, business and operational uncertainty, including customer spending behavior which have created, and continue to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities. See "Forward-Looking Statements" below.
Conference Call and Earnings Webcast Presentation Details
Amdocs will host a conference call and earnings webcast presentation on May 13, 2026 at 5:00 p.m. Eastern Time to discuss the Company's second quarter of fiscal 2026 results. To participate in the call, please register here to receive the dial-in numbers and unique access PIN. The conference call and webcast will also be carried live on the Internet and may be accessed via the Amdocs website at https://investors.amdocs.com. Presentation slides will be available shortly before the webcast.
Non-GAAP Financial Measures
This release includes non-GAAP financial measures, including non-GAAP diluted earnings per share, free cash flow(2), revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth. These other non-GAAP measures exclude the following items:
amortization of purchased intangible assets and other acquisition-related costs;
changes in certain acquisition-related liabilities measured at fair value;
restructuring and unusual charges or benefits;
equity-based compensation expense;
other; and
tax effects related to the above.
Free cash flow(2) equals cash generated by operating activities less net capital expenditures. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures.
Amdocs believes that the presentation of non-GAAP financial measures, including non-GAAP diluted earnings per share, free cash flow(2), revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business.
For its internal budgeting process and in monitoring the results of the business, Amdocs' management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition-related liabilities measured at fair value, restructuring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs' management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items.
Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below.
Supporting Resources
Keep up with Amdocs news by visiting the Company's website
Subscribe to Amdocs' RSS Feed and follow us on Twitter, Facebook, LinkedIn and YouTube
About Amdocs
Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ:DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.
Forward-Looking Statements
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' strategy, including with respect to artificial intelligence and agentic opportunities, growth, financial outlook, and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks, uncertainties, and other important factors that may cause future results to differ materially from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers, Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and our Form 6-K furnished for the first quarter of fiscal 2026 on February 17, 2026.
Contact:
Matthew Smith
Head of Investor Relations
Amdocs
314-212-8328
E-mail: [email protected]
AMDOCS LIMITED
Consolidated Statements of Income
(In thousands, except per share data)
Three months ended
March 31,
Six months ended
March 31,
2026
2025
2026
2025
Revenue
$
1,171,979
$
1,128,203
$
2,327,918
$
2,238,258
Operating expenses:
Cost of revenue
716,733
698,049
1,444,456
1,380,308
Research and development
87,001
81,796
168,979
166,129
Selling, general and administrative
153,677
134,625
267,398
256,712
Amortization of purchased intangible assets and other
21,308
15,998
35,842
31,757
Restructuring charges
10,405
-
21,706
6,783
989,124
930,468
1,938,381
1,841,689
Operating income
182,855
197,735
389,537
396,569
Interest and other expense, net
(5,963
)
(8,465
)
(17,228
)
(14,874
)
Income before income taxes
176,892
189,270
372,309
381,695
Income taxes
38,120
25,269
75,083
65,842
Net income
$
138,772
$
164,001
$
297,226
$
315,853
Net income attributable to noncontrolling interests
957
758
1,845
1,477
Net income attributable to Amdocs Limited
$
137,815
$
163,243
$
295,381
$
314,376
Basic earnings per share attributable to Amdocs Limited
$
1.29
$
1.46
$
2.75
$
2.80
Diluted earnings per share attributable to Amdocs Limited
$
1.28
$
1.45
$
2.74
$
2.78
Cash dividends declared per ordinary share
$
0.569
$
0.527
$
1.096
$
1.006
Basic weighted average number of shares outstanding
107,095
111,961
107,541
112,357
Diluted weighted average number of shares outstanding
107,472
112,514
107,997
112,981
AMDOCS LIMITED
Selected Financial Metrics
(In thousands, except per share data)
Three months ended
March 31,
Six months ended
March 31,
2026
2025
2026
2025
Revenue
$
1,171,979
$
1,128,203
$
2,327,918
$
2,238,258
Non-GAAP operating income
251,836
240,106
501,775
475,504
Non-GAAP net income
192,501
201,017
389,632
389,894
Non-GAAP net income attributable to Amdocs Limited
191,544
200,259
387,787
388,417
Non-GAAP diluted earnings per share
$
1.78
$
1.78
$
3.59
$
3.44
Diluted weighted average number of shares outstanding
107,472
112,514
107,997
112,981
Free Cash Flows
(In thousands)
Three months ended
March 31,
Six months ended
March 31,
2026
2025
2026
2025
Net Cash Provided by Operating Activities
$
101,584
$
172,458
$
321,766
$
278,013
Purchases of property and equipment, net (a)
(21,237
)
(15,964
)
(53,476
)
(43,319
)
Free Cash Flow
$
80,347
$
156,494
$
268,290
$
234,694
(a) The amounts under "Purchase of property and equipment, net", include immaterial proceeds from sale of property and equipment for the three and six months ended March 31, 2026 and 2025, respectively.
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)
Three Months Ended March 31, 2026
GAAP
Amortization
of purchased intangible assets and other
Equity based compensation
expense
Changes in certain acquisitions
related liabilities measured at fair value
Restructuring charges
Other
Tax
effect
Non-GAAP
Operating expenses:
Cost of revenue
$
716,733
$
-
$
(11,392
)
$
(135
)
$
-
$
-
$
-
$
705,206
Research and development
87,001
(2,068
)
84,933
Selling, general and administrative
153,677
(24,539
)
866
130,004
Amortization of purchased intangible assets and other
21,308
(21,308
)
-
Restructuring charges
10,405
(10,405
)
-
Total operating expenses
989,124
(21,308
)
(37,999
)
731
(10,405
)
-
-
920,143
Operating income
182,855
21,308
37,999
(731
)
10,405
251,836
Interest and other expense, net
(5,963
)
(7,637
)
(13,600
)
Income taxes
38,120
7,615
45,735
Net income
138,772
21,308
37,999
(731
)
10,405
(7,637
)
(7,615
)
192,501
Net income attributable to noncontrolling interests
957
957
Net income attributable to Amdocs Limited
$
137,815
$
21,308
$
37,999
$
(731
)
$
10,405
$
(7,637
)
$
(7,615
)
$
191,544
Three Months Ended March 31, 2025
GAAP
Amortization
of purchased intangible assets and other
Equity based compensation
expense
Changes in certain acquisitions
related liabilities measured at fair value
Other
Tax
effect
Non-GAAP
Operating expenses:
Cost of revenue
$
698,049
$
-
$
(12,356
)
$
(360
)
$
-
$
-
$
685,333
Research and development
81,796
(2,283
)
79,513
Selling, general and administrative
134,625
(11,014
)
(360
)
123,251
Amortization of purchased intangible assets and other
15,998
(15,998
)
-
Restructuring charges
-
-
Total operating expenses
930,468
(15,998
)
(25,653
)
(720
)
-
-
888,097
Operating income
197,735
15,998
25,653
720
240,106
Interest and other expense, net
(8,465
)
(69
)
(8,534
)
Income taxes
25,269
5,286
30,555
Net income
164,001
15,998
25,653
720
(69
)
(5,286
)
201,017
Net income attributable to noncontrolling interests
758
758
Net income attributable to Amdocs Limited
$
163,243
$
15,998
$
25,653
$
720
$
(69
)
$
(5,286
)
$
200,259
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)
Six Months Ended March 31, 2026
GAAP
Amortization
of purchased intangible assets and other
Equity based
compensation
expense
Changes in certain acquisitions
related liabilities measured at fair value
Restructuring
charges
Other
Tax
effect
Non-GAAP
Operating expenses:
Cost of revenue
$
1,444,456
$
-
$
(22,765
)
$
(494
)
$
-
$
-
$
-
$
1,421,197
Research and development
168,979
(3,927
)
165,052
Selling, general and administrative
267,398
(35,397
)
7,893
239,894
Amortization of purchased intangible assets and other
35,842
(35,842
)
-
Restructuring charges
21,706
(21,706
)
-
Total operating expenses
1,938,381
(35,842
)
(62,089
)
7,399
(21,706
)
-
-
1,826,143
Operating income
389,537
35,842
62,089
(7,399
)
21,706
501,775
Interest and other expense, net
(17,228
)
(6,064
)
(23,292
)
Income taxes
75,083
13,768
88,851
Net income
297,226
35,842
62,089
(7,399
)
21,706
(6,064
)
(13,768
)
389,632
Net income attributable to noncontrolling interests
1,845
1,845
Net income attributable to Amdocs Limited
$
295,381
$
35,842
$
62,089
$
(7,399
)
$
21,706
$
(6,064
)
$
(13,768
)
$
387,787
Six Months Ended March 31, 2025
GAAP
Amortization
of purchased intangible assets and other
Equity based
compensation
expense
Changes in certain acquisitions
related liabilities measured at fair value
Restructuring
charges
Other
Tax
effect
Non-GAAP
Operating expenses:
Cost of revenue
$
1,380,308
$
-
$
(25,606
)
$
(360
)
$
-
$
-
$
-
$
1,354,342
Research and development
166,129
(4,554
)
161,575
Selling, general and administrative
256,712
(22,013
)
12,138
246,837
Amortization of purchased intangible assets and other
31,757
(31,757
)
-
Restructuring charges
6,783
(6,783
)
-
Total operating expenses
1,841,689
(31,757
)
(52,173
)
11,778
(6,783
)
-
-
1,762,754
Operating income
396,569
31,757
52,173
(11,778
)
6,783
475,504
Interest and other expense, net
(14,874
)
5,979
(8,895
)
Income taxes
65,842
10,873
76,715
Net income
315,853
31,757
52,173
(11,778
)
6,783
5,979
(10,873
)
389,894
Net income attributable to noncontrolling interests
1,477
1,477
Net income attributable to Amdocs Limited
$
314,376
$
31,757
$
52,173
$
(11,778
)
$
6,783
$
5,979
$
(10,873
)
$
388,417
AMDOCS LIMITED
Condensed Consolidated Balance Sheets
(In thousands)
As of
March 31,
2026
September 30,
2025
ASSETS
Current assets:
Cash and cash equivalents
$
214,495
$
324,999
Accounts receivable, net, including unbilled
938,182
935,751
Prepaid expenses and other current assets
364,347
331,387
Total current assets
1,517,024
1,592,137
Property and equipment, net
738,836
768,557
Lease assets
179,580
182,088
Goodwill and other intangible assets, net
3,243,895
3,046,962
Other noncurrent assets
684,535
660,086
Total assets
$
6,363,870
$
6,249,830
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable, accruals and other
$
1,108,842
$
1,201,206
Short-term financing arrangements
250,000
-
Lease liabilities
36,017
38,725
Deferred revenue
152,434
118,861
Total current liabilities
1,547,293
1,358,792
Lease liabilities
134,567
140,776
Long-term debt, net of unamortized debt issuance costs
647,211
646,901
Other noncurrent liabilities
611,376
632,681
Total Amdocs Limited Shareholders' equity
3,382,292
3,429,453
Noncontrolling interests
41,131
41,227
Total equity
3,423,423
3,470,680
Total liabilities and equity
$
6,363,870
$
6,249,830
AMDOCS LIMITED
Consolidated Statements of Cash Flows
(In thousands)
Six months ended
March 31,
2026
2025
Cash Flow from Operating Activities:
Net income
$
297,226
$
315,853
Reconciliation of net income to net cash provided by operating activities:
Depreciation, amortization and impairment
103,747
94,460
Amortization of debt issuance cost
310
300
Equity-based compensation expense
62,089
52,173
Deferred income taxes
24,148
2,296
Loss from short-term interest-bearing investments
-
1,739
Net changes in operating assets and liabilities, net of amounts acquired:
Accounts receivable, net
(46,640
)
33,174
Prepaid expenses and other current assets
(23,114
)
(32,526
)
Other noncurrent assets
18,492
5,141
Lease assets and liabilities, net
(6,408
)
(1,194
)
Accounts payable, accrued expenses and accrued personnel
(90,120
)
(126,700
)
Deferred revenue
23,505
27,846
Income taxes payable, net
(5,003
)
(11,082
)
Other noncurrent liabilities
(36,466
)
(83,467
)
Net cash provided by operating activities
$
321,766
$
278,013
Cash Flow from Investing Activities:
Purchase of property and equipment, net (a)
(53,476
)
(43,319
)
Proceeds from sale of short-term interest-bearing investments
-
92,955
Net cash paid for business and intangible assets acquisitions
(217,663
)
(57,169
)
Net cash from equity investments and other
11,848
16,741
Net cash (used) provided by investing activities
$
(259,291
)
$
9,208
Cash Flow from Financing Activities:
Repurchase of shares
(284,513
)
(279,720
)
Proceeds from employee stock option exercises
3,193
11,422
Payments of dividends
(113,849
)
(107,810
)
Distribution to noncontrolling interests
(1,941
)
(2,209
)
Borrowings under financing arrangements
250,000
-
Payment of contingent consideration and deferred payment of business acquisitions
(25,869
)
(7,599
)
Net cash used in financing activities
$
(172,979
)
$
(385,916
)
Net decrease in cash and cash equivalents
(110,504
)
(98,695
)
Cash and cash equivalents at beginning of period
324,999
346,085
Cash and cash equivalents at end of period
$
214,495
$
247,390
AMDOCS LIMITED
Supplementary Information
(In millions)
Through this collaboration, the service provider will strengthen its operational resilience, improve service agility, and enhance customer experiences
JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs (NASDAQ:DOX), a leading provider of software and services for communications and media companies, today announced a strategic multi-year agreement with Telefónica Móviles Argentina to support its operational excellence journey through a comprehensive modernization program.
As part of the agreement, Amdocs will deliver Product Maintenance Services, Application Managed Services, and Software Factory capabilities, ensuring service continuity while enabling the Argentine service provider to evolve its technology landscape continually.
The program will enable Telefónica Móviles Argentina to continue to operate on an up-to-date version of Amdocs' full-stack solutions, incorporating the latest software enhancements, security updates, and architectural improvements.
This initiative will establish a robust, standardized, and future-ready foundation, ensuring stable day-to-day operations while supporting the ongoing evolution of Telefónica Móviles Argentina's network systems.
"This agreement marks a significant step forward in our operational excellence journey," said Diego Martinez, CTIO at Telefónica Móviles Argentina. "With Amdocs' expertise and continued innovation, we are enhancing our end-to-end customer management processes while significantly reducing billing cycle times. These improvements are driving meaningful efficiencies across our operations, enabling faster time-to-market and greater agility in delivering new services. At the same time, Amdocs' support in maintaining and evolving our technology stack ensures we can provide a more seamless, reliable, and high-quality experience to our customers."
"This multi-year agreement marks an important step in enabling Telefónica Móviles Argentina to combine ongoing innovation with seamless operational scale," said Anthony Goonetilleke, Group President of Technology and Head of Strategy at Amdocs. "Through this collaboration, Telefónica Móviles Argentina will be well-positioned to deliver reliable, high‑quality experiences as customer expectations continue to evolve."
Supporting Resources
Keep up with Amdocs news by visiting the company's website
Follow us on X, Facebook, LinkedIn, and YouTube
About Amdocs
Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ: DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.
Amdocs' Forward-Looking Statement
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and for the first quarter of fiscal 2026 on February 17, 2026.
The inventory modernization will enhance operational efficiency and accelerate network planning, rollout, and assurance for Vodafone Ireland, ensuring future readiness while aligning with the broader strategic objectives of the Vodafone Group
JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs (NASDAQ:DOX), a leading provider of software and services for communications and media companies, announced today that Vodafone Ireland has successfully gone live with Amdocs' latest Network Inventory solution as part of its initiative to modernize, harmonize, and evolve its network operations. This collaboration has replaced Vodafone Ireland's legacy system with the latest version of the Amdocs Network Inventory, empowering the Irish service provider to accelerate and automate the planning, deployment, and assurance of its mobile network and drive operational efficiency across the organization.
Amdocs Network Inventory, a cornerstone in enabling agile and autonomous networks, will serve as the foundation for harmonizing Vodafone Ireland's inventory models and processes with those of other Vodafone Group countries across Europe. By standardizing and streamlining systems and best practices, Vodafone Ireland aims to reduce the total cost of ownership, streamline operations, and deliver an enhanced user experience powered by automation, federation, and an intuitive user interface.
Leveraging a proven ‘develop-once-deploy-many' co-designed framework, Amdocs successfully delivered a high-impact project, harmonizing network operations and topology, in alignment with Vodafone Group's strategic network vision. In close collaboration with Vodafone Ireland and Vodafone Group teams, Amdocs modernized the existing inventory platform, executing a complex data migration and cleansing initiative with exceptional speed and precision.
This milestone reflects the strength of the partnership between Amdocs and Vodafone, as well as Amdocs' commitment to driving innovation and operational excellence across Vodafone's global network footprint.
"By moving to Amdocs' modern network inventory solution, we are strengthening our ability to plan, build, and manage our network more efficiently," said Sheila Kavanagh, Chief Network Officer at Vodafone Ireland. "This upgrade not only helps us deliver better service to our customers today, but also ensures we're well-prepared for tomorrow's connectivity demands."
"With service providers worldwide increasingly focused on autonomous networks, we're delighted to continue our collaboration with Vodafone Ireland as they progress through their network transformation journey," said Anthony Goonetilleke, Group President of Technology and Head of Strategy at Amdocs. "This go-live marks a key milestone in Vodafone's broader digital evolution, enabling greater automation, faster time to market, and seamless integration across group operations."
Supporting Resources
Learn more about Amdocs Network Inventory, here
Keep up with Amdocs news by visiting the company's website
Follow us on X, Facebook, LinkedIn, and YouTube
About Amdocs
Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ:DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.
Amdocs' Forward-Looking Statement
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and for the first quarter of fiscal 2026 on February 17, 2026.
With Amdocs connectX, Qué tal Móvil's new platform accelerates time to market while enabling seamless integrations, flexible payments, and improved customer access across a growing partner ecosystem
JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs (NASDAQ:DOX), a leading provider of software and services for communications and media companies, today announced that Qué tal Móvil, a US-based Mobile Virtual Network Operator (MVNO), has successfully launched a new multi-aggregator, multi-payment, and multi-channel activation platform, enabled by the Amdocs connectX platform and delivered in collaboration with PartnerSolve.
The new platform enables Qué tal Móvil to seamlessly integrate with multiple aggregation partners - including MVNO Connect and Helix Wireless - while supporting a wide range of payment methods and sales channels across the full subscriber lifecycle. This includes new activations, number portability, refills, and additional transaction types, all delivered through a scalable and flexible architecture.
By leveraging Amdocs connectX, Qué tal Móvil has been able to simplify operational complexity and accelerate its go-to-market strategy, enabling rapid onboarding of partners and expansion of commercial offerings.
"With Amdocs connectX, we were able to focus on growing our business and executing our marketing strategy, while relying on a robust platform to manage the complexity behind the scenes," said Daniel Barsoum, CEO at Qué tal Móvil. "The speed of deployment and minimal upfront investment allowed us to launch quickly and scale with confidence."
The implementation also incorporates PartnerSolve's integration framework, enabling open and extensible connectivity across multiple ecosystem partners.
"This project represents a significant milestone in building a universal integration layer that connects MVNOs with a broad ecosystem of partners," said Andy Hopkins, Founder of PartnerSolve. "Our goal is to unlock new revenue opportunities and provide MVNOs with the tools they need to scale efficiently and remain competitive."
"Enabling Qué tal Móvil to go to market with a robust, AI‑enabled connectivity offering is a testament to the power of the Amdocs connectX platform," said Anthony Goonetilleke, Group President of Technology and Head of Strategy at Amdocs. "By leveraging connectX to facilitate agentic activation, Qué tal Móvil is demonstrating real innovation in how MVNOs can scale faster, differentiate their services, and deliver smarter customer experiences in an increasingly competitive market."
Supporting Resources
Learn more about Amdocs connectX, here
Keep up with Amdocs news by visiting the company's website
Follow us on X, Facebook, LinkedIn, and YouTube
About Amdocs
Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ: DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.
About Qué tal Móvil
Qué tal Móvil provides wireless plans and services designed to keep customers connected, with a strong focus on serving diverse communities, including native Spanish-speaking customers. For more information, visit www.quetalmovil.com.
About PartnerSolve
PartnerSolve is a management consulting firm specializing in back-office operations, integration, and control frameworks. The company enables organizations to build scalable, connected ecosystems and optimize end-to-end operations. Learn more at: www.partnersolve.com.
Amdocs' Forward-Looking Statement
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and for the first quarter of fiscal 2026 on February 17, 2026.
Media Contacts
Mario Hajiloizi
Amdocs Public Relations
E-mail: [email protected]
The agents, built using Google's AI models, enable enterprise-scale deployment of agentic AI across telecom workflows
JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today announced the availability of Amdocs Telco Agents for Customer Experience in the Google Gemini Enterprise Agent Marketplace, Google Cloud's platform for building and deploying enterprise-grade AI agents.
These agents are now featured as part of Google Cloud's partner-built agents ecosystem in Gemini Enterprise, as announced at Google Cloud Next 2026, underscoring Amdocs' role in shaping the next wave of enterprise AI innovation. Built on Google Cloud's Gemini Enterprise platform, Amdocs Telco Agents for Customer Experience enable communications service providers (CSPs) to automate key customer-facing and operational processes, including customer care interactions, service request handling, issue resolution, and order orchestration.
The agents can reason, orchestrate, and execute end‑to‑end telco processes, improving resolution speed, cost efficiency, and customer satisfaction across digital and contact center channels. Built on aOS, Amdocs' agentic operating system for telcos, the solution combines Amdocs' Cognitive Core with Gemini Enterprise for CX to coordinate workflows across existing BSS/OSS systems and AI ecosystems. As the intelligence layer within aOS, Amdocs Cognitive Core applies telco-specific reasoning and governance to support scalable AI deployment within live telecom operations.
"Enterprise customers need AI solutions that are not only powerful but also secure, scalable, and easy to deploy," said Satish Thomas, Vice President, Applied AI & Platform Ecosystem, Google Cloud. "This collaboration brings together Google Cloud's cutting-edge AI capabilities with Amdocs' proven industry expertise, offering communications service providers an accelerated path to deploying agentic AI at scale."
"We're thrilled to be among a strategic group of companies globally to publish agents on Gemini Enterprise. This reinforces our agentic AI strategy to help CSPs move beyond traditional AI assistants toward autonomous systems that can execute complex service workflows end-to-end," said Anthony Goonetilleke, Group President of Technology and Head of Strategy at Amdocs. "By combining Amdocs' telecom expertise with Google Cloud's AI, these agents reduce handling time, improve first call resolution, and enable proactive issue prevention, while maintaining enterprise-grade trust, governance, and security."
Supporting Resources
Read more about aOS, here
Keep up with Amdocs news by visiting the company's website
Follow us on X, Facebook, LinkedIn, and YouTube
About Amdocs
Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ: DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.
Amdocs' Forward-Looking Statement
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and for the first quarter of fiscal 2026 on February 17, 2026.
Deployment supports Lumen's cloud transformation by enhancing scalability, resilience, and operational efficiency for enterprise services through AI‑assisted cloud migration
JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs (NASDAQ:DOX), a leading provider of software and services for communications and digital service providers, today announced that Lumen Technologies is accelerating its cloud-first strategy with Amdocs, expanding the migration of mission-critical platforms to the public cloud with the migration of one of its enterprise billing platforms to Microsoft Azure.
This engagement builds on the ongoing collaboration between Lumen and Amdocs and represents a continued step in Lumen's strategy to transition mission-critical enterprise platforms to the public cloud. The initiative supports Lumen's cloud-first strategy by using Microsoft Azure to enhance resilience, improve operational agility, and enable greater scalability, while maintaining the reliability required for customer-critical workloads.
Lumen's billing platform plays a central role in supporting its enterprise revenue operations, making this migration a key milestone in evolving Lumen's enterprise platform landscape to support growing demand and innovation.
As part of the engagement, Amdocs will apply its agentic, AI-enabled migration capabilities through Amdocs Operating System framework (aOS) to accelerate complex cloud journeys, reduce transformation risk, and embed continuous optimization from day one.
"Enterprise billing is a foundational capability for how we serve our business customers. By working with Amdocs to migrate one of our billing platforms to Microsoft Azure, we are strengthening resiliency and scalability while improving operational efficiency," said Chad Naeger, Chief Information Officer at Lumen.
"As Lumen advances its multi-cloud transformation, partners like Amdocs play a critical role in helping us migrate and modernize mission-critical applications and platforms across Microsoft Azure, Google Cloud, and AWS," said Sulabh Sood, Vice President of Cloud Transformation at Lumen.
"We are proud to continue supporting Lumen in advancing its cloud strategy by migrating its mission-critical enterprise billing platform to Microsoft Azure," said Anthony Goonetilleke, Group President of Technology and Head of Strategy at Amdocs. "This engagement reflects Amdocs' role as a long-term partner in operating and evolving core consumer and business platforms, ensuring reliability while enabling scalable growth in the cloud."
Supporting Resources
Keep up with Amdocs news by visiting the company's website
Follow us on X, Facebook, LinkedIn, and YouTube
About Amdocs
Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ: DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.
Amdocs' Forward-Looking Statement
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and for the first quarter of fiscal 2026 on February 17, 2026.
Supporting 12,000 transactions per second across three active cloud regions, the Amdocs Entitlement Server sets a new benchmark on Microsoft Azure for performance, reliability, and availability needed by large telecom operators to confidently launch and sustain eSIM services at scale
JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs (NASDAQ:DOX), a leading provider of software and services for communications and media companies, today announced that its Entitlement Server, the core of the Amdocs eSIM Cloud, has achieved a sustained 12,000 Transactions Per Second (TPS) across three geographically distributed Microsoft Azure regions in a production-grade, active-active deployment. This milestone represents one of the highest publicly benchmarked throughput levels for a carrier-grade entitlement server.
Achieved in collaboration with Microsoft and aligned with Azure's Well-Architected Framework, the benchmark demonstrates the platform's ability to deliver sub-second latency, continuous availability, and resilience at scale, even during peak demand events such as device launches, mass eSIM activations, and nationwide Rich Communication Services (RCS) rollouts.
As the entitlement server evolves into a strategic control point between devices, networks, and digital services, performance and resilience have become critical differentiators. Industry recognition reflects this shift, with Counterpoint Research naming Amdocs the #1 Pacesetter in both the 2025 Entitlement Server and eSIM Orchestration rankings.
This benchmark highlights a new standard for evaluating entitlement platforms: sustained throughput and multi-region resilience under real production load. As eSIM adoption accelerates across smartphones, wearables, vehicles, and IoT, operators require platforms that can scale to billions of transactions without compromise.
Built as a cloud-based software platform (SaaS), the Amdocs Entitlement Server is designed to deliver the scale and reliability required by large telecom operators. Its modular architecture and automated cloud management enable it to scale on demand, introduce updates without service interruptions, and quickly launch new services. The platform supports the full range of entitlement capabilities - from eSIM activation and device pairing to advanced messaging (RCS), voice services over LTE and Wi-Fi (VoLTE/VoWiFi), 5G network capabilities, and emerging satellite connectivity - all within a single, proven platform used by operators worldwide. The Entitlement Server leverages the latest technology from the Amdocs aOS Cognitive Core, ensuring efficient scale and seamless operations.
Key benchmark highlights include:
Active-active deployment across three Azure regions, helping to ensure continuous service with no failover disruption
99.999% availability, meeting Tier-1 operator requirements for mission-critical services
Validation against Azure's Well-Architected Framework for reliability, security, and performance
"This achievement reinforces our commitment to delivering proven, carrier-grade platforms for the world's largest operators," said Anthony Goonetilleke, Group President of Technology and Head of Strategy, Amdocs. "The Entitlement Server brings the same cloud-native and AI-enabled foundations that span our portfolio, capitalizing on Amdocs aOS and Cognitive Core capabilities. "Together with Microsoft, we are enabling service providers to scale confidently and support the next wave of digital services."
"This benchmark demonstrates what becomes possible when carrier-grade telecom workloads are architected for the hyperscale cloud from the ground up," said Igal Figlin, Corporate Vice President - Azure Compute at Microsoft. "By engineering the Amdocs Entitlement Server to the standards of our Well-Architected Framework across three active Azure regions, we've proven that the most demanding telco operations can run with the same resilience and elasticity that the world's largest digital enterprises expect."
Supporting Resources
Learn more about Amdocs eSIM on Microsoft Marketplace, here
Keep up with Amdocs news by visiting the company's website
Follow us on X, Facebook, LinkedIn, and YouTube
About Amdocs
Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ:DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com.
Amdocs' Forward-Looking Statement
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and for the first quarter of fiscal 2026 on February 17, 2026.
Amdocs NASDAQ: DOX reported fiscal second-quarter 2026 revenue and non-GAAP earnings above the midpoint of its guidance, while newly appointed Chief Executive Officer Shimie Hortig used the company’s earnings call to outline a strategy centered on “agentic” artificial intelligence for telecom operators.
The software and services provider said revenue for the quarter was approximately $1.172 billion, up 3.9% year over year as reported and 2.2% in constant currency. Non-GAAP diluted earnings per share were $1.78, $0.02 above the midpoint of the company’s guidance. GAAP diluted EPS was $1.28.
Get Amdocs alerts:
Hortig said Amdocs’ results reflected “solid” execution, with growth in North America, record revenue in Europe and a strong performance in Rest of World. The company ended the quarter with 12-month backlog of $4.28 billion, up $30 million sequentially and 2.6% from a year earlier.
Amdocs Sets Focus on Agentic AI for Telecom Hortig, who recently stepped into the CEO role, described the current wave of agentic AI as a major opportunity for communications service providers to transform IT and network systems, simplify complexity and speed the launch of new offerings.
“I strongly believe that Amdocs is in the best position to lead our customers and turn this agentic opportunity into reality,” Hortig said, citing the company’s telecom domain expertise, engineering background, experience with mission-critical systems and history of outcome-based customer engagements.
The company recently launched aOS, its Amdocs Agentic Operating System for telecom, at Mobile World Congress. Hortig said Amdocs has already signed initial commercial agreements to launch and implement aOS with customers including Cricket, Lumen, Bell Canada, EchoStar and PLDT.
At PLDT, Hortig said early results showed that more than 90% of customer requests are now resolved through the aOS platform, enabling faster handling times and higher productivity in retail stores.
In response to analyst questions, Hortig said aOS opportunities are starting small and are not yet a meaningful contributor to the current fiscal year outlook, but he said customer discussions are expanding. Some customers are discussing broader responsibilities for Amdocs to help transform operations and deliver savings and business benefits, he said.
Quarter Includes New Deals and Project Milestones Amdocs highlighted several customer wins and extensions during the quarter. Hortig said the company signed an expanded multi-year managed services agreement with AT&T’s Cricket Wireless, including dealer onboarding modernization intended to improve partner experience and support faster market expansion.
Other deals cited on the call included a five-year agreement with Vodafone Spain covering CRM and OSS modernization, along with support and enhancement services. In South Korea, KT extended a multi-year agreement with Amdocs to upgrade, modernize and operate its charging system, supporting faster service rollout and 5G monetization.
The company also pointed to momentum for its cloud-based platform offerings. Hortig said connectX added new customers including Vantta Wireless, which plans to launch a mobile service with AT&T using AI-driven connectivity, and Cuatro Mobile, a U.S.-based MVNO serving Hispanic communities. A leading operator in Singapore also went live with the platform, he said.
Amdocs eSIM was selected by Cielo in Brazil for payment terminal connectivity and by MobiFone in Vietnam for zero-touch customer activation, according to Hortig.
The company also reported project milestones with customers including AT&T, Optimum, Vodafone Germany, Elisa and PLDT. Hortig said Amdocs is now servicing a significant portion of AT&T’s 5G standalone subscribers on its next-generation charging platform and played a role in the launch of AT&T’s OneConnect plan. Brightspeed also went live with Amdocs Resource Manager.
Margins Improve as Company Invests in AI Chief Financial and Operating Officer Tamar Rapaport-Dagim said non-GAAP operating margin was 21.5%, up 20 basis points from a year ago. She attributed the improvement to cost and efficiency gains from operational excellence, automation and AI-based tools, while noting the company is also investing in its aOS platform.
Managed services revenue was $759 million, up 1.6% from the prior year and representing roughly 65% of total revenue, consistent with recent quarters. Rapaport-Dagim said renewal rates remained “typically high” during the quarter.
Regionally, North America revenue was $754 million, up more than 2% year over year but slightly lower sequentially due to normal fluctuations in customer activity. Europe revenue reached a record $192 million, up more than 6% year over year, reflecting organic growth and the impact of the Matrix acquisition. Rest of World revenue rose 8% to $226 million, the highest since fiscal third-quarter 2024.
Cash Flow, Capital Returns and Acquisition Amdocs reported free cash flow before restructuring payments of $97 million in the quarter. Including $17 million of restructuring payments, reported free cash flow was $80 million. Rapaport-Dagim said the company has already achieved nearly 50% of its fiscal 2026 free cash flow target.
The company repurchased $138 million of shares during the quarter and paid $57 million in cash dividends. As of March 31, 2026, Amdocs had up to $702 million of remaining repurchase authority.
Amdocs also acquired the business of Connect44, a European provider of end-to-end network planning, building and management solutions, for approximately $21 million net in cash at closing, plus potential future contingent consideration.
The company ended the quarter with approximately $214 million in cash and aggregate borrowings of roughly $900 million, including $650 million in senior notes due June 2030 and $250 million in short-term financing arrangements. Amdocs also established a U.S. commercial paper program of up to $800 million and upsized its revolving credit facility to $800 million.
Guidance Reaffirmed, CFO Transition Announced Amdocs reiterated the midpoint of its full-year fiscal 2026 constant-currency revenue growth guidance at 3%, while tightening the range to 2% to 4%. On a reported basis, the company now expects revenue growth of 2.6% to 4.6%, with foreign currency expected to provide a roughly 0.6% benefit.
For the third fiscal quarter, Amdocs guided for revenue of $1.155 billion to $1.195 billion. The company also reiterated the midpoint of its fiscal 2026 non-GAAP diluted EPS growth outlook at approximately 6%, within a tightened range of 5% to 7%.
Rapaport-Dagim said Amdocs expects fiscal 2026 free cash flow of $710 million to $730 million, excluding payments under its current restructuring program, and expects to return the majority of free cash flow to shareholders.
The call also included the announcement of a CFO transition. Rapaport-Dagim said she plans to retire after nearly 20 years as CFO and 22 years overall with Amdocs. Hortig thanked her for her service and said Tal Rosenfeld, a 20-year Amdocs finance executive, will become the company’s next CFO.
“I believe he’s undoubtedly the best person for this role,” Rapaport-Dagim said, adding that she had been preparing Rosenfeld for the position as part of an internal succession plan.
About Amdocs NASDAQ: DOXAmdocs NASDAQ: DOX is a global software and services provider specializing in solutions for communications, media and entertainment companies. The company designs, develops and integrates revenue management, customer experience and digital services platforms that enable service providers to launch and monetize new offerings, streamline operations and enhance subscriber engagement. Amdocs' product suite encompasses billing and order management, customer relationship management, digital commerce and network function virtualization, supported by professional services for implementation, integration and managed operations.
Founded in 1982 and structured as a separate public company in 1998, Amdocs has its corporate headquarters in Chesterfield, Missouri, and maintains major development centers in Ra'anana, Israel.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Amdocs Right Now?Before you consider Amdocs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.
While Amdocs currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.
Amdocs (DOX - Free Report) came out with quarterly earnings of $1.78 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $1.78 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +0.85%. A quarter ago, it was expected that this provider of computer systems integration would post earnings of $1.75 per share when it actually produced earnings of $1.81, delivering a surprise of +3.43%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Amdocs, which belongs to the Zacks Computers - IT Services industry, posted revenues of $1.17 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.44%. This compares to year-ago revenues of $1.13 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Amdocs shares have lost about 22.6% since the beginning of the year versus the S&P 500's gain of 8.1%.
What's Next for Amdocs?While Amdocs has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Amdocs was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.88 on $1.18 billion in revenues for the coming quarter and $7.44 on $4.7 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Computers - IT Services is currently in the bottom 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Endava PLC Sponsored ADR (DAVA - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 21.
This company is expected to post quarterly earnings of $0.27 per share in its upcoming report, which represents a year-over-year change of -37.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Endava PLC Sponsored ADR's revenues are expected to be $249.69 million, up 1.8% from the year-ago quarter.
For the quarter ended March 2026, Amdocs (DOX - Free Report) reported revenue of $1.17 billion, up 3.9% over the same period last year. EPS came in at $1.78, compared to $1.78 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.17 billion, representing a surprise of +0.44%. The company delivered an EPS surprise of +0.85%, with the consensus EPS estimate being $1.77.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Amdocs performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenue- North America: $754.3 million versus $769.07 million estimated by two analysts on average.Geographic Revenue- Rest of the World: $225.8 million versus $204.24 million estimated by two analysts on average.Geographic Revenue- Europe: $191.8 million versus $192.49 million estimated by two analysts on average.View all Key Company Metrics for Amdocs here>>>
Shares of Amdocs have returned -4.1% over the past month versus the Zacks S&P 500 composite's +8.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Key Takeaways Amdocs Q2 FY26 EPS of $1.78 beat estimates, whereas revenues rose 3.9% y/y.Amdocs reported revenue growth across North America, Europe and Rest of World.The FY26 outlook calls for 2.6-4.6% revenue growth and a 5-7% EPS expansion. Amdocs Limited (DOX - Free Report) reported better-than-expected second-quarter fiscal 2026 results. DOX’s non-GAAP earnings of $1.78 per share came above the midpoint of management’s guidance of $1.73-$1.79 and remained flat on a year-over-year basis. The figure also surpassed the Zacks Consensus Estimate of $1.77.
Amdocs’ fiscal second-quarter revenues of $1.172 billion topped the consensus mark of $1.167 billion and came above the midpoint of management’s guidance of $1.15-$1.19 billion. The top line increased 3.9% on a reported basis and 2.2% on a constant-currency basis.
Amdocs’ Q2 DetailsDOX reported growth in revenues across North America, Europe and the Rest of the World (RoW). North America reported revenues of $754.3 million (64.4% of the total revenues), which increased 2.2% year over year. Europe revenues (16.4% of the total revenues) of $191.8 million advanced 6.1% year over year.
RoW revenues (19.2% of the total revenues) increased 7.9% year over year to $225.8 million. Our model estimates for North America, Europe and RoW were pinned at $766.6 million, $204.3 million and $195.1 million, respectively.
Managed services revenues rose 1.6% year over year to $758.7 million. The company ended the second quarter of fiscal 2026 with a 12-month backlog of $4.28 billion, up $30 million sequentially. Our model estimates for managed services revenues and backlog were pegged at $767.3 million and $4.27 billion, respectively.
The non-GAAP operating income increased 5% year over year to $252 million, whereas the operating margin expanded 20 basis points to 21.5%.
DOX’s Balance Sheet & Cash FlowAmdocs had cash and cash equivalents of $214.5 million as of March 31, 2026, compared with $247.9 million as of Dec. 31, 2025. Long-term debt was $647.2 million as of March 31, 2026, increasing marginally from the Dec. 31, 2025, level of $647 million.
In the fiscal second quarter, the company generated an operating cash flow of $101.6 million and a free cash flow of $80.3 million. During the quarter, it repurchased shares worth $138 million and paid out $57 million in dividends.
Amdocs Updates FY26 GuidanceFor fiscal 2026, DOX expects revenues to grow 2.6-4.6% compared with the earlier mentioned 1.5-5.5% rise. The Zacks Consensus Estimate for revenues is pegged at $4.7 billion, suggesting a year-over-year increase of 3.7%.
The non-GAAP operating margin is anticipated to be 21.3-21.9% for fiscal 2026. Non-GAAP earnings per share are expected to grow 5-7%, instead of the earlier stated 4-8% range. The Zacks Consensus Estimate for earnings is pegged at $7.44 per share, indicating a year-over-year rise of 6.4%.
The company expects the free cash flow between $710 million and $730 million.
Amdocs also initiated the guidance for the third quarter of fiscal 2026. For the fiscal third quarter, the company expects revenues of $1.155-$1.195 billion. The Zacks Consensus Estimate for revenues is pegged at $1.18 billion, suggesting a year-over-year jump of 3.1%.
Amdocs expects non-GAAP earnings per share between $1.81 and $1.87. The Zacks Consensus Estimate is pegged at $1.88 per share, indicating a year-over-year rise of 9.3%.
DOX’s Zacks Rank & Stocks to ConsiderCurrently, Amdocs carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Zacks Computer and Technology sector are Broadcom (AVGO - Free Report) , Celestica (CLS - Free Report) and Amphenol (APH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of Broadcom have gained 20.4% year to date. The Zacks Consensus Estimate for Broadcom’s 2026 earnings is pegged at $11.45 per share, up by a penny over the past 30 days, indicating a year-over-year surge of 67.9%.
Shares of Celestica have gained 26% year to date. The Zacks Consensus Estimate for Celestica’s 2026 earnings is pegged at $10.16 per share, up 15.1% over the past 30 days, indicating a year-over-year jump of 67.9%.
Amphenol shares have declined 7.7% year to date. The Zacks Consensus Estimate for APH’s 2026 earnings is pegged at $4.76 per share, up 11.4% over the past 30 days, indicating a year-over-year increase of 42.5%.
Analysis of 180,000 Patients Validates Measurement-Informed Care for Anxiety and Depression
, /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of outpatient mental health care, published new clinical outcomes data demonstrating that LifeStance patients treated for anxiety and depression broadly experienced clinically significant improvements in their symptoms.
The analysis included nearly 180,000 patients who initiated care between September 2024 and December 2025 across the 33 states LifeStance serves. Key findings include:
Anxiety improvement: 79% of LifeStance patients showed clinically significant improvements in symptoms of anxiety* Depression improvement: 73% of LifeStance patients showed clinically significant improvements in symptoms of depression* Results were consistent across all U.S. geographic regions *Among 140,000 individuals with at least moderate anxiety and 150,000 individuals with at least moderate depression.
Patients were evaluated using two widely used mental health screening tools: the GAD-7 for anxiety and the PHQ-9 for depression. Through LifeStance's measurement‑informed care model, patients complete GAD‑7 and PHQ‑9 assessments at regular intervals, allowing clinicians to track progress over time and adjust care as needed.
LifeStance is committed to clinical excellence and delivering high-quality care. Its model is designed to support improved patient outcomes, including in-person and telehealth options to expand access and support patient engagement; integrated therapy and medication management for more comprehensive and personalized care; and measurement-informed practices that allow clinicians to track and adjust treatment over time.
"For too long, patients seeking mental health care have not had the same clear way to track progress that exists in other areas of medicine, like a blood pressure reading or an A1C result," said Dr. Stephanie Eken, Chief Medical Officer, LifeStance. "Measurement-informed care is changing that dynamic. Our data shows that when patients receive high-quality mental health care, they get better—and LifeStance is demonstrating that at scale."
The full anxiety and depression treatment outcomes analysis is available at LifeStance.com.
About LifeStance
Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation's largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. LifeStance and its supported practices employ approximately 8,000 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 33 states and more than 550 centers.
Contacts:
Media relations: [email protected]
Investor relations: [email protected]
LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) has been given an average rating of “Moderate Buy” by the nine brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $9.8333.
LFST has been the subject of a number of recent research reports. UBS Group boosted their price objective on shares of LifeStance Health Group from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Wall Street Zen raised shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Canaccord Genuity Group boosted their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Jefferies Financial Group raised shares of LifeStance Health Group to a “strong-buy” rating in a research report on Thursday, March 12th. Finally, Weiss Ratings raised shares of LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 27th.
View Our Latest Stock Analysis on LFST
LifeStance Health Group Price Performance Shares of LFST opened at $6.40 on Monday. The firm has a market cap of $2.49 billion, a PE ratio of 320.16 and a beta of 1.13. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17. The firm has a fifty day simple moving average of $6.76 and a two-hundred day simple moving average of $6.47. LifeStance Health Group has a 1-year low of $3.74 and a 1-year high of $8.09.
LifeStance Health Group (NASDAQ:LFST – Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). The company had revenue of $382.20 million for the quarter, compared to analysts’ expectations of $378.51 million. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.65%. LifeStance Health Group’s quarterly revenue was up 17.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.01) earnings per share. On average, equities analysts anticipate that LifeStance Health Group will post -0.18 EPS for the current year.
LifeStance Health Group announced that its Board of Directors has initiated a share repurchase plan on Wednesday, February 25th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to reacquire up to 3.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.
Insider Activity In other news, Director Darren M. Black sold 4,314,939 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $7.01, for a total transaction of $30,247,722.39. Following the completion of the sale, the director owned 29,209,776 shares of the company’s stock, valued at $204,760,529.76. The trade was a 12.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 3.20% of the stock is currently owned by insiders.
Institutional Inflows and Outflows Several hedge funds have recently bought and sold shares of LFST. Royal Bank of Canada boosted its holdings in LifeStance Health Group by 63.4% in the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock worth $468,000 after buying an additional 27,244 shares during the period. AQR Capital Management LLC boosted its holdings in LifeStance Health Group by 223.0% in the 1st quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after buying an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in LifeStance Health Group by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock worth $952,000 after buying an additional 4,169 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in LifeStance Health Group by 1.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock worth $4,100,000 after buying an additional 11,331 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in LifeStance Health Group by 10.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 550,657 shares of the company’s stock worth $2,847,000 after buying an additional 51,154 shares during the period. Institutional investors own 85.50% of the company’s stock.
LifeStance Health Group Company Profile (Get Free Report)
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
See Also Five stocks we like better than LifeStance Health Group
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEVEON (VEON) & The Competition Financial Survey
NEXT HEADLINE »Svenska Handelsbanken Ab Publ (OTCMKTS:SVNLY) Receives Consensus Recommendation of “Reduce” from Brokerages
Chemed (NYSE:CHE – Get Free Report) and LifeStance Health Group (NASDAQ:LFST – Get Free Report) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.
Institutional & Insider Ownership 95.9% of Chemed shares are held by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are held by institutional investors. 3.3% of Chemed shares are held by insiders. Comparatively, 6.6% of LifeStance Health Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations This is a summary of current ratings and target prices for Chemed and LifeStance Health Group, as reported by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemed 2 2 2 0 2.00 LifeStance Health Group 0 2 6 1 2.89 Chemed currently has a consensus target price of $498.00, suggesting a potential upside of 18.38%. LifeStance Health Group has a consensus target price of $9.83, suggesting a potential upside of 39.48%. Given LifeStance Health Group’s stronger consensus rating and higher possible upside, analysts clearly believe LifeStance Health Group is more favorable than Chemed.
Earnings & Valuation This table compares Chemed and LifeStance Health Group”s top-line revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemed $2.53 billion 2.43 $265.24 million $18.35 22.92 LifeStance Health Group $1.42 billion 1.92 $9.66 million $0.02 352.50 Chemed has higher revenue and earnings than LifeStance Health Group. Chemed is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk Chemed has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, LifeStance Health Group has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Profitability This table compares Chemed and LifeStance Health Group’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Chemed 10.23% 27.18% 17.38% LifeStance Health Group 0.68% 0.65% 0.45% Summary Chemed beats LifeStance Health Group on 8 of the 15 factors compared between the two stocks.
About Chemed (Get Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
About LifeStance Health Group (Get Free Report)
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINELondon Stock Exchange Group plc – Unsponsored ADR (OTCMKTS:LNSTY) Receives Average Recommendation of “Buy” from Analysts
NEXT HEADLINE »Speed Commerce (OTCMKTS:SPDC) versus A2Z Cust2Mate Solutions (NASDAQ:AZ) Head to Head Comparison
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
APA Corporation (APA - Free Report) : This energy company has seen the Zacks Consensus Estimate for its current year earnings increasing 105.8% over the last 60 days.
Marathon Petroleum Corporation (MPC - Free Report) : This energy company has seen the Zacks Consensus Estimate for its current year earnings increasing 76% over the last 60 days.
Phillips 66 (PSX - Free Report) : This integrated downstream energy company has seen the Zacks Consensus Estimate for its current year earnings increasing 21.6% over the last 60 days.
LifeStance Health Group, Inc. (LFST - Free Report) : This mental healthcare services provider has seen the Zacks Consensus Estimate for its current year earnings increasing 50% over the last 60 days.
Galp Energia, SGPS, S.A. (GLPEY - Free Report) : This integrated energy company has seen the Zacks Consensus Estimate for its current year earnings increasing 41.1% over the last 60 days.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check out this week’s current list of Best Stocks to Buy Now.
